http://www.cas.org/infopolicy.html

```
=> s l35 and (py<2003 or ay<2003 or pry<2003)
      22929897 PY<2003
       4481535 AY<2003
       3956985 PRY<2003
L42          56 L35 AND (PY<2003 OR AY<2003 OR PRY<2003)

=> d ibib abs hitstr 1-
YOU HAVE REQUESTED DATA FROM 56 ANSWERS - CONTINUE? Y/(N):y

L42  ANSWER 1 OF 56  CAPLUS  COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER:         2008:10367  CAPLUS <<LOGINID::20080505>>
DOCUMENT NUMBER:          148:93277
TITLE:                    Histone deacetylase inhibitors for treating
                          degenerative diseases of the eye
INVENTOR(S):              Hellberg, Peggy E.
PATENT ASSIGNEE(S):       Alcon, Inc., Switz.
SOURCE:                   U.S. Pat. Appl. Publ., 8pp., Cont.-in-part of U.S.
                          Ser. No. 694,309.
                          CODEN: USXXCO
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   3
PATENT INFORMATION:

     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     ----------------    ----   --------    --------------------   --------
     US 20080004311       A1    20080103    US 2007-836309         20070809 <--
     US 20040092431       A1    20040513    US 2003-694309         20031027 <--
     CA 2504226           A1    20040527    CA 2003-2504226        20031027 <--
     AU 2003286686        A1    20040603    AU 2003-286686         20031027 <--
     EP 1562592           A2    20050817    EP 2003-777895         20031027 <--
          R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
              IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
     BR 2003016163        A     20050927    BR 2003-16163          20031027 <--
     JP 2006508120        T     20060309    JP 2004-551572         20031027 <--
     US 20070088045       A1    20070419    US 2005-531747         20050418 <--
     MX 2005PA04738       A     20050803    MX 2005-PA4738         20050503 <--
     IN 2007DN07459       A     20071109    IN 2007-DN7459         20070927 <--
PRIORITY APPLN. INFO.:                       US 2002-425576P     P  20021112 <--
                                             US 2003-694309      A2 20031027
                                             WO 2003-US33873     W  20031027
                                             IN 2005-DN2543      A3 20050613
AB   The invention discloses compns. and methods for treating degenerative
     conditions and diseases of the eye with histone deacetylase inhibitors.
IT   149647-78-9, SAHA
     RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
     (Biological study); USES (Uses)
        (histone deacetylase inhibitors for treatment of degenerative eye
        diseases)
RN   149647-78-9  CAPLUS
CN   Octanediamide, N1-hydroxy-N8-phenyl-  (CA INDEX NAME)
```



IT 9076-57-7, Histone deacetylase
RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; histone deacetylase inhibitors for treatment of degenerative eye diseases)
RN 9076-57-7 CAPLUS
CN Deacetylase, histone (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L42 ANSWER 2 OF 56 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:705011 CAPLUS <<LOGINID::20080505>>
DOCUMENT NUMBER: 147:125824
TITLE: Controlled release solid oral dosage form containing a histone deacetylase inhibitor and a medium chain fatty acid derivative as an absorption enhancer
INVENTOR(S): Cumming, Kenneth I.; Ramtoola, Zebunnissa; Leonard, Thomas Waymond
PATENT ASSIGNEE(S): Merrion Research I Limited, Ire.
SOURCE: U.S. Pat. Appl. Publ., 35pp., Cont.-in-part of U.S. Ser. No. 510,560.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 20070148228	A1	20070628	US 2006-450641		20060609 <--
US 20030091623	A1	20030515	US 2000-510560		20000222 <--
PRIORITY APPLN. INFO.:			US 1999-121048P	P	19990222 <--
			US 2000-510560	A2	20000222 <--

AB The invention relates to a pharmaceutical composition and oral dosage forms comprising an histone deacetylase (HDAC) inhibitor in combination with an enhancer to promote absorption of the HDAC inhibitor at the gastrointestinal tract cell lining. The enhancer is a medium chain fatty acid or a medium chain fatty acid derivative having a carbon chain length of from 6 to 20 carbon atoms. Preferably, the solid oral dosage form is a controlled release dosage form such as a delayed release dosage form. Thus, granules comprising 61.05% parnaparin sodium, 33.95% sodium caprate and 5% polyvinylpyrrolidone were prepared and administered orally to humans. The mean delivery of parnaparin, as measured by plasma anti-factor Xa levels, was considerably higher from the solid dosage form than that from the corresponding solution dosage.
IT 149647-78-9, Suberoylanilide hydroxamic acid 382180-17-8 , Pyroxamide 537049-40-4, Tubacin
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(controlled release solid oral dosage form comprising a histone

deacetylase inhibitor and a medium chain fatty acid derivative as an absorption enhancer)

RN 149647-78-9 CAPLUS
CN Octanediamide, N1-hydroxy-N8-phenyl- (CA INDEX NAME)



RN 382180-17-8 CAPLUS
CN Octanediamide, N1-hydroxy-N8-3-pyridinyl- (CA INDEX NAME)



RN 537049-40-4 CAPLUS
CN Octanediamide, N1-[4-[(2R,4R,6S)-4-[[(4,5-diphenyl-2-oxazolyl)thio]methyl]-6-[4-(hydroxymethyl)phenyl]-1,3-dioxan-2-yl]phenyl]-N8-hydroxy-, rel- (CA INDEX NAME)

Relative stereochemistry.



IT 9076-57-7, Histone deacetylase
RL: BSU (Biological study, unclassified); BIOL (Biological study)

(inhibitor; controlled release solid oral dosage form comprising a histone deacetylase inhibitor and a medium chain fatty acid derivative as an absorption enhancer)
RN 9076-57-7 CAPLUS
CN Deacetylase, histone (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L42 ANSWER 3 OF 56 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:356698 CAPLUS <<LOGINID::20080505>>
DOCUMENT NUMBER: 146:372833
TITLE: Histone deacetylase inhibitor or histone hyperacetylating agent for promoting wound healing and preventing scar formation
INVENTOR(S): Chung, Yih-Lin
PATENT ASSIGNEE(S): Taiwan
SOURCE: U.S. Pat. Appl. Publ., 36pp., Cont.-in-part of U.S. Ser. No. 205,738.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
US 20070072793	A1	20070329	US 2004-843025	20040510	<--
US 20040018958	A1	20040129	US 2002-205738	20020725	<--
US 6809118	B2	20041026			
US 20060275370	A1	20061207	US 2006-499936	20060807	<--
PRIORITY APPLN. INFO.:			US 2002-205738	A2 20020725	<--
			US 2004-798119	A2 20040311	
			US 2004-843025	A2 20040510	

AB The invention discloses a method for promoting wound healing and preventing scar formation in a variety of wounds in skin, mucosa, and cornea. The method comprises administering a therapeutically effective amount of a histone deacetylase inhibitor or a hyperacetylating agent. The histone deacetylase inhibitor or hyperacetylating agent is capable of stimulating multiple cytokines/growth factors in the early phase of wound healing, and suppressing fibrogenic cytokines/growth factors in the late phase of tissue remodeling in the wound site, and is useful in promoting epithelial cell regrowth and reducing excessive collagen accumulation, which results in rapid wound closure with reduced scaring.
IT 9076-57-7, Histone deacetylase
RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); BIOL (Biological study)
(histone deacetylase inhibitor or histone hyperacetylating agent for promoting wound healing and preventing scar formation, and use with other agents)
RN 9076-57-7 CAPLUS
CN Deacetylase, histone (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
IT 149647-78-9, Suberoylanilide hydroxamic acid
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(histone deacetylase inhibitor or histone hyperacetylating agent for promoting wound healing and preventing scar formation, and use with other agents)

RN 149647-78-9 CAPLUS

CN Octanediamide, N1-hydroxy-N8-phenyl- (CA INDEX NAME)



L42 ANSWER 4 OF 56 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:1284568 CAPLUS <<LOGINID::20080505>>

DOCUMENT NUMBER: 146:50305

TITLE: Method and compositions for treatment of epithelial damage

INVENTOR(S): Chung, Yih-Lin; Pui, Nam-Mew

PATENT ASSIGNEE(S): Taiwan

SOURCE: U.S. Pat. Appl. Publ., 14pp., Cont.-in-part of U.S. Ser. No. 843,025.
CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20060275370	A1	20061207	US 2006-499936	20060807 <--
US 20040018958	A1	20040129	US 2002-205738	20020725 <--
US 6809118	B2	20041026		
US 20050272644	A1	20051208	US 2004-798119	20040311 <--
US 20070072793	A1	20070329	US 2004-843025	20040510 <--
PRIORITY APPLN. INFO.:			US 2002-205738 A2	20020725 <--
			US 2004-798119 A2	20040311
			US 2004-843025 A2	20040510

AB The present invention is directed to methods and compns. of treating or preventing epithelial lining tissue damage from dermatitis or mucositis induced by radiation exposure and/or chemotherapy, by applying to skin, mucosa or other tissues of the body an amount of a therapeutic composition which comprises a histone deacetylase inhibitor formulated with at least one pharmaceutically acceptable biocompatible polymer or carrier, or pharmaceutically acceptable salts in an amount sufficient to delay onset or decrease severity of the signs and symptoms of dermatitis and mucositis in cancer therapy. Such therapeutic compns. have the advantage of prolonged retention and sustained action of the histone deacetylase inhibitor in the skin, mucosa or other tissues of the body. The invention is also directed to treatment and prevention of gastrointestinal distress and cancer-related fatigue syndrome that are associated with mucositis in cancer therapy.

IT 9076-57-7

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(inhibitor; method and compns. for treatment of epithelial damage)
RN 9076-57-7 CAPLUS
CN Deacetylase, histone (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
IT 149647-78-9, Suberoylanilide hydroxamic acid
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(method and compns. for treatment of epithelial damage)
RN 149647-78-9 CAPLUS
CN Octanediamide, N1-hydroxy-N8-phenyl- (CA INDEX NAME)



L42 ANSWER 5 OF 56 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:1355554 CAPLUS <<LOGINID::20080505>>
DOCUMENT NUMBER: 144:81158
TITLE: Use of thioredoxin measurements for diagnostics and treatments
INVENTOR(S): Marks, Paul A.; Ungerstedt, Johanna
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 39 pp., Cont.-in-part of U.S. Ser. No. 369,094.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE	
US 20050288227	A1	20051229	US 2005-144301		20050603	<--
US 20030235588	A1	20031225	US 2003-369094		20030214	<--
US 20060009526	A1	20060112	US 2005-223405		20050909	<--
US 20060009527	A1	20060112	US 2005-223547		20050909	<--
PRIORITY APPLN. INFO.:			US 2002-357383P	P	20020215	<--
			US 2003-369094	A2	20030214	
			US 2004-577089P	P	20040604	

AB The invention relates to methods for monitoring patient response to histone deacetylase inhibitors (e.g., suberoylanilide hydroxamic acid (SAHA)) or other therapeutic agents by measuring the level of thioredoxin in body fluids, tissues, and/or cells, such as peripheral blood mononuclear cells, plasma, or serum. The invention also relates to methods of monitoring and/or assisting with the diagnosis of a wide variety of thioredoxin-related diseases and conditions, such as inflammatory diseases, allergic diseases, autoimmune diseases, diseases associated with oxidative stress or diseases characterized by cellular hyperproliferation.
IT 9076-57-7, Histone deacetylase
RL: BSU (Biological study, unclassified); BIOL (Biological study)

(use of thioredoxin expression measurements for diagnostics and monitoring treatments with histone deacetylase inhibitors and other therapeutic agents for hyperproliferative diseases)
RN 9076-57-7 CAPLUS
CN Deacetylase, histone (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
IT 149647-78-9, Suberoylanilide hydroxamic acid 382180-17-8
, Pyroxamide
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(use of thioredoxin expression measurements for diagnostics and monitoring treatments with histone deacetylase inhibitors and other therapeutic agents for hyperproliferative diseases)
RN 149647-78-9 CAPLUS
CN Octanediamide, N1-hydroxy-N8-phenyl- (CA INDEX NAME)



RN 382180-17-8 CAPLUS
CN Octanediamide, N1-hydroxy-N8-3-pyridinyl- (CA INDEX NAME)



L42 ANSWER 6 OF 56 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:1292833 CAPLUS <<LOGINID::20080505>>
DOCUMENT NUMBER: 144:32206
TITLE: Method using histone deacetylase inhibitors for increasing therapeutic gain in radiotherapy and chemotherapy
INVENTOR(S): Chung, Yih-Lin
PATENT ASSIGNEE(S): Taiwan
SOURCE: U.S. Pat. Appl. Publ., 37 pp., Cont.-in-part of U.S. Ser. No. 205,738.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

US 20050272644	A1	20051208	US 2004-798119	20040311	<--
US 20040018958	A1	20040129	US 2002-205738	20020725	<--
US 6809118	B2	20041026			
US 20060275370	A1	20061207	US 2006-499936	20060807	<--

PRIORITY APPLN. INFO.: US 2002-205738 A2 20020725 <--
US 2004-798119 A2 20040311
US 2004-843025 A2 20040510

AB The invention provides compns. and methods for increasing therapeutic gain in radiotherapy and chemotherapy for proliferating malignant or nonmalignant disease to produce high probability of tumor control with low frequency of sequelae of therapy by administering a therapeutically effective amount of a histone deacetylase inhibitor. The compds. are capable of simultaneously stimulating epithelial regrowth, inhibiting fibroblast proliferation, decreasing collagen deposits, suppressing fibrogenic growth factor, subsiding proinflammatory cytokine, and modulating expression of cell cycle genes, tumor suppressors and oncogenes, and are useful for increasing the therapeutic gain in radiotherapy and chemotherapy, which results in decrease of skin swelling and inflammation, promotion of epithelial healing in mucosa and dermis, decrease of xerostomia, prevention/reduction of severity of plantar-palmar syndrome, prevention of tissue fibrosis, ulceration, necrosis and tumorigenesis, and increase of tumor growth inhibition and tumor therapy effectiveness.

IT 149647-78-9, Suberoylanilide hydroxamic acid
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(histone deacetylase inhibitors for increasing therapeutic gain in radiotherapy and chemotherapy)

RN 149647-78-9 CAPLUS

CN Octanediamide, N1-hydroxy-N8-phenyl- (CA INDEX NAME)



IT 9076-57-7, Histone deacetylase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; histone deacetylase inhibitors for increasing therapeutic gain in radiotherapy and chemotherapy)

RN 9076-57-7 CAPLUS

CN Deacetylase, histone (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L42 ANSWER 7 OF 56 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER:	2005:1103330 CAPLUS <<LOGINID::20080505>>
DOCUMENT NUMBER:	143:379844
TITLE:	Methods using deacetylase inhibitors for treating neurodegenerative diseases and motor deficit disorders
INVENTOR(S):	Steffan, Joan S.; Thompson, Leslie M.; Marsh, J. Lawrence; Bodai, Laszlo; Pallos, Judit; Hockly, Emma; Bates, Gillian
PATENT ASSIGNEE(S):	USA

SOURCE: U.S. Pat. Appl. Publ., 52 pp., Cont.-in-part of U.S. Ser. No. 476,627.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20050227915	A1	20051013	US 2004-768292	20040129 <--
WO 2002090534	A1	20021114	WO 2002-US14167	20020502 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 20040142859	A1	20040722	US 2003-476627	20031030 <--

PRIORITY APPLN. INFO.:			
US 2001-288215P	P	20010502	<--
US 2002-372724P	P	20020411	<--
WO 2002-US14167	W	20020502	<--
US 2003-443717P	P	20030129	
US 2003-476627	A2	20031030	

OTHER SOURCE(S): MARPAT 143:379844

AB The invention discloses a method for treating a variety of diseases and disorders, including polyglutamine expansion diseases such as Huntington's disease, neurol. degeneration, psychiatric disorders, and protein aggregation disorders and diseases, comprising administering to patients in need thereof a therapeutically effective amount of one or more deacetylase inhibitors. The invention is also directed to a transgenic fly useful as a model of polyglutamine expansion diseases, which may be used to test potential therapeutic agents.

IT 9076-57-7, Histone deacetylase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(deacetylase inhibitors for treating neurodegenerative diseases and motor deficit disorders)

RN 9076-57-7 CAPLUS
CN Deacetylase, histone (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 149647-78-9, Suberoylanilide hydroxamic acid 149647-78-9D, Suberoylanilide hydroxamic acid, derivs. 382180-17-8, Pyroxamide 382180-17-8D, Pyroxamide, derivs.
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(deacetylase inhibitors for treating neurodegenerative diseases and motor deficit disorders)

RN 149647-78-9 CAPLUS
CN Octanediamide, N1-hydroxy-N8-phenyl- (CA INDEX NAME)



RN 149647-78-9 CAPLUS
CN Octanediamide, N1-hydroxy-N8-phenyl- (CA INDEX NAME)



RN 382180-17-8 CAPLUS
CN Octanediamide, N1-hydroxy-N8-3-pyridinyl- (CA INDEX NAME)



RN 382180-17-8 CAPLUS
CN Octanediamide, N1-hydroxy-N8-3-pyridinyl- (CA INDEX NAME)



L42 ANSWER 8 OF 56 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:177856 CAPLUS <<LOGINID::20080505>>
DOCUMENT NUMBER: 142:254579
TITLE: Method of treating cancer with histone deacetylase (HDAC) inhibitors
INVENTOR(S): Bacopoulos, Nicholas G.; Chiao, Judy H.; Miller, Thomas A.; Paradise, Carolyn M.; Richon, Victoria M.
PATENT ASSIGNEE(S): Aton Pharma, Inc., USA; Sloan-Kettering Institute for Cancer Research
SOURCE: PCT Int. Appl., 107 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 7
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
WO 2005018578	A2	20050303	WO 2004-US27943	20040826	
WO 2005018578	A3	20050512			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
US 20040087631	A1	20040506	US 2003-650025	20030826	<--
US 7148257	B2	20061212			
US 20040127523	A1	20040701	US 2003-665079	20030916	<--
AU 2004266169	A1	20050303	AU 2004-266169	20040826	
AU 2004266169	A2	20060406			
AU 2004266169	B2	20070503			
AU 2004266169	B9	20070510			
CA 2535806	A1	20050303	CA 2004-2535806	20040826	
EP 1663194	A2	20060607	EP 2004-782425	20040826	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK					
BR 2004013826	A	20061024	BR 2004-13826	20040826	
CN 1870985	A	20061129	CN 2004-80031306	20040826	
JP 2007518694	T	20070712	JP 2006-524891	20040826	
KR 2007029617	A	20070314	KR 2006-703748	20060224	
MX 2006PA02234	A	20060801	MX 2006-PA2234	20060227	
NO 2006001348	A	20060523	NO 2006-1348	20060324	
US 20070060614	A1	20070315	US 2006-567952	20061117	<--
AU 2007203525	A1	20070816	AU 2007-203525	20070726	
AU 2007203648	A1	20070823	AU 2007-203648	20070803	

PRIORITY APPLN. INFO.:			
US 2003-650025	A1	20030826	
US 2003-665079	A1	20030916	
US 2002-361759P	P	20020304	<--
AU 2003-213684	A3	20030304	
US 2003-379149	A2	20030304	
AU 2004-266169	A3	20040826	
WO 2004-US27943	W	20040826	

OTHER SOURCE(S): MARPAT 142:254579

AB The invention discloses methods for treating cancers, e.g. mesothelioma or lymphoma. More specifically, the invention discloses methods for treating mesothelioma or diffuse large B-cell lymphoma (DLBCL), by administration of pharmaceutical compns. comprising HDAC inhibitors, e.g., suberoylanilide hydroxamic acid (SAHA; preparation described). The oral formulations of the pharmaceutical compns. have favorable pharmacokinetic profiles such as high bioavailability and surprisingly give rise to high blood levels of the active compds. over an extended period of time. The invention further provides a safe, daily dosing regimen of these pharmaceutical compns., which is easy to follow, and which results in a

therapeutically effective amount of the HDAC inhibitors in vivo.
IT 149647-78-9P, Saha
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(histone deacetylase inhibitors for cancer treatment)
RN 149647-78-9 CAPLUS
CN Octanediamide, N1-hydroxy-N8-phenyl- (CA INDEX NAME)



IT 9076-57-7, Histone deacetylase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(histone deacetylase inhibitors for cancer treatment)
RN 9076-57-7 CAPLUS
CN Deacetylase, histone (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
IT 382180-17-8, Pyroxamide
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(histone deacetylase inhibitors for cancer treatment)
RN 382180-17-8 CAPLUS
CN Octanediamide, N1-hydroxy-N8-3-pyridinyl- (CA INDEX NAME)



L42 ANSWER 9 OF 56 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:701812 CAPLUS <<LOGINID::20080505>>
DOCUMENT NUMBER: 141:167803
TITLE: Treatment of lung cells with histone deacetylase inhibitors
INVENTOR(S): Wiech, Norbert L.; Lan-Hargest, Hsuan-Yin
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 10 pp., Cont.-in-part of U.S. Ser. No. 25,947.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 9
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20040167184	A1	20040826	US 2003-715377	20031119 <--
US 7314953	B2	20080101		
US 20020143196	A1	20021003	US 2001-812944	20010327 <--
US 6495719	B2	20021217		
US 20020143052	A1	20021003	US 2001-812945	20010327 <--
US 7312247	B2	20071225		
US 20020143037	A1	20021003	US 2001-25947	20011226 <--
US 20030083521	A1	20030501	US 2002-307321	20021202 <--
PRIORITY APPLN. INFO.:			US 2001-812940	B1 20010327 <--
			US 2001-812944	A3 20010327 <--
			US 2001-812945	A2 20010327 <--
			US 2001-25947	A2 20011226 <--
			US 2002-427567P	P 20021120 <--
			US 2002-307321	B2 20021202 <--

OTHER SOURCE(S): MARPAT 141:167803

AB Lung disease, such as cystic fibrosis, chronic obstructive pulmonary disease, asthma, or acute and chronic bronchitis, can be treated with an oxyamide-containing compound Preparation of e.g. 5-phenyl-2,4-pentadienoylhydroxamic acid is described.

IT 9076-57-7, Histone deacetylase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(Treatment of lung cells with histone deacetylase inhibitors)

RN 9076-57-7 CAPLUS

CN Deacetylase, histone (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 149647-78-9, SAHA
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Treatment of lung cells with histone deacetylase inhibitors)

RN 149647-78-9 CAPLUS

CN Octanediamide, N1-hydroxy-N8-phenyl- (CA INDEX NAME)



L42 ANSWER 10 OF 56 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:550755 CAPLUS <<LOGINID::20080505>>

DOCUMENT NUMBER: 141:82311

TITLE: Methods of treating cancer with histone deacetylase (HDAC) inhibitors

INVENTOR(S): Bacopoulos, Nicholas G.; Chiao, Judy H.; Miller, Thomas A.; Paradise, Carolyn M.; Richon, Victoria M.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 53 pp., Cont.-in-part of U.S. Pat. Appl. 2004 72,735.
CODEN: USXXCO

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 7
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20040132825	A1	20040708	US 2003-692523	20031024 <--
US 20040072735	A1	20040415	US 2003-379149	20030304 <--
AU 2004283717	A2	20050506	AU 2004-283717	20041022
AU 2004283717	A1	20050506		
CA 2543319	A1	20050506	CA 2004-2543319	20041022
WO 2005039498	A2	20050506	WO 2004-US35181	20041022
WO 2005039498	A3	20051124		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, US				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1689379	A2	20060816	EP 2004-796215	20041022
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
CN 1901895	A	20070124	CN 2004-80039156	20041022
JP 2007509171	T	20070412	JP 2006-536858	20041022
IN 2006DN02367	A	20070803	IN 2006-DN2367	20060428
AU 2007203525	A1	20070816	AU 2007-203525	20070726
AU 2007203648	A1	20070823	AU 2007-203648	20070803

PRIORITY APPLN. INFO.:	US 2002-361759P	P	20020304 <--
	US 2003-379149	A2	20030304
	AU 2003-213684	A3	20030304
	US 2003-692523	A	20031024
	AU 2004-266169	A3	20040826
	WO 2004-US35181	W	20041022

OTHER SOURCE(S): MARPAT 141:82311

AB The invention discloses methods for treating cancers, e.g. leukemia. More specifically, the invention relates to methods of treating acute and chronic leukemias including Acute Lymphocytic Leukemia (ALL), Acute Myeloid Leukemia (AML), Chronic Lymphocytic leukemia (CLL), Chronic myeloid leukemia (CML) and Hairy Cell Leukemia, by administration of pharmaceutical compns. comprising HDAC inhibitors, e.g., suberoylanilide hydroxamic acid (SAHA; preparation described). The oral formulations of the pharmaceutical compns. have favorable pharmacokinetic profiles such as high bioavailability and surprisingly give rise to high blood levels of the active compds. over an extended period. The invention further provides a safe, daily dosing regimen of these pharmaceutical compns., which is easy to follow, and which results in a therapeutically effective amount of the HDAC inhibitors in vivo.

IT 9076-57-7, Histone deacetylase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(histone deacetylase inhibitors for treatment of cancer)

RN 9076-57-7 CAPLUS
CN Deacetylase, histone (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
IT 149647-78-9P, Suberoylanilide hydroxamic acid
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(histone deacetylase inhibitors for treatment of cancer)
RN 149647-78-9 CAPLUS
CN Octanediamide, N1-hydroxy-N8-phenyl- (CA INDEX NAME)



IT 382180-17-8, Pyroxamide
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(histone deacetylase inhibitors for treatment of cancer)
RN 382180-17-8 CAPLUS
CN Octanediamide, N1-hydroxy-N8-3-pyridinyl- (CA INDEX NAME)



L42 ANSWER 11 OF 56 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:533980 CAPLUS <<LOGINID::20080505>>
DOCUMENT NUMBER: 141:65091
TITLE: Methods of treating cancer with histone deacetylase (HDAC) inhibitors
INVENTOR(S): Bacopoulos, Nicholas G.; Chiao, Judy H.; Miller, Thomas A.; Paradise, Carolyn M.; Richon, Victoria M.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 54 pp., Cont.-in-part of U.S. Ser. No. 379,149.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 7
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20040127523	A1	20040701	US 2003-665079	20030916 <--

```
     US 20040072735          A1    20040415    US 2003-379149          20030304 <--
     AU 2004266169           A1    20050303    AU 2004-266169          20040826
     AU 2004266169           A2    20060406
     AU 2004266169           B2    20070503
     AU 2004266169           B9    20070510
     CA 2535806              A1    20050303    CA 2004-2535806         20040826
     WO 2005018578           A2    20050303    WO 2004-US27943         20040826
     WO 2005018578           A3    20050512
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
             NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
             TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
             AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
             EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
             SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
             SN, TD, TG
     EP 1663194              A2    20060607    EP 2004-782425          20040826
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK
     BR 2004013826           A     20061024    BR 2004-13826           20040826
     CN 1870985              A     20061129    CN 2004-80031306        20040826
     JP 2007518694           T     20070712    JP 2006-524891          20040826
     KR 2007029617           A     20070314    KR 2006-703748          20060224
     MX 2006PA02234          A     20060801    MX 2006-PA2234          20060227
     NO 2006001348           A     20060523    NO 2006-1348            20060324
     US 20060276547          A1    20061207    US 2006-492478          20060724 <--
     US 20070060614          A1    20070315    US 2006-567952          20061117 <--
     AU 2007203525           A1    20070816    AU 2007-203525          20070726
     AU 2007203648           A1    20070823    AU 2007-203648          20070803
PRIORITY APPLN. INFO.:                           US 2002-361759P     P  20020304 <--
                                                 US 2003-379149      A2 20030304
                                                 AU 2003-213684      A3 20030304
                                                 US 2003-650025      A  20030826
                                                 US 2003-665079      A  20030916
                                                 AU 2004-266169      A3 20040826
                                                 WO 2004-US27943     W  20040826
```

OTHER SOURCE(S): MARPAT 141:65091

AB The invention relates to methods of treating cancers, e.g., lymphoma. More specifically, the present invention relates to methods of treating diffuse large B-cell lymphoma (DLBCL), by administration of pharmaceutical compns. comprising HDAC inhibitors, e.g., suberoylanilide hydroxamic acid (preparation described). The oral formulations of the pharmaceutical compns. have favorable pharmacokinetic profiles such as high bioavailability and surprisingly give rise to high blood levels of the active compds. over an extended period of time. The present invention further provides a safe, daily dosing regimen of these pharmaceutical compns., which is easy to follow, and which results in a therapeutically effective amount of the HDAC inhibitors in vivo.

IT 9076-57-7, Histone deacetylase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(histone deacetylase inhibitors for treatment of cancer)

RN 9076-57-7 CAPLUS

CN Deacetylase, histone (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
IT 149647-78-9P, SAHA
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(histone deacetylase inhibitors for treatment of cancer)
RN 149647-78-9 CAPLUS
CN Octanediamide, N1-hydroxy-N8-phenyl- (CA INDEX NAME)



IT 382180-17-8, Pyroxamide
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(histone deacetylase inhibitors for treatment of cancer)
RN 382180-17-8 CAPLUS
CN Octanediamide, N1-hydroxy-N8-3-pyridinyl- (CA INDEX NAME)



L42 ANSWER 12 OF 56 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:533979 CAPLUS <<LOGINID::20080505>>
DOCUMENT NUMBER: 141:65090
TITLE: Methods of treating cancer with histone deacetylase (HDAC) inhibitors
INVENTOR(S): Chiao, Judy H.; Bacopoulos, Nicholas G.; Miller, Thomas A.; Paradise, Carolyn M.; Richon, Victoria M.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 56 pp., Cont.-in-part of U.S. Ser. No. 379,149.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 7
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20040127522	A1	20040701	US 2003-616649	20030709 <--
US 20040072735	A1	20040415	US 2003-379149	20030304 <--
AU 2007203525	A1	20070816	AU 2007-203525	20070726

AU 2007203648 A1 20070823 AU 2007-203648 20070803
PRIORITY APPLN. INFO.: US 2002-361759P P 20020304 <--
US 2003-379149 A2 20030304
AU 2003-213684 A3 20030304
AU 2004-266169 A3 20040826
OTHER SOURCE(S): MARPAT 141:65090
AB The invention provides methods for treating cancers, chemoprevention, selectively inducing terminal differentiation, cell growth arrest and/or apoptosis of neoplastic cells, and/or inhibiting histone deacetylase (HDAC) by administration of pharmaceutical compns. comprising potent HDAC inhibitors. The oral bioavailability of the active compds. in the pharmaceutical compns. of the invention is surprisingly high. Moreover, the pharmaceutical compns. unexpectedly give rise to high, therapeutically effective blood levels of the active compds. over an extended period of time. The invention further provides a safe, daily dosing regimen of these pharmaceutical compns., which is easy to follow, and which results in a therapeutically effective amount of the HDAC inhibitors in vivo. Compds. of the invention include e.g. suberoylanilide hydroxamic acid (preparation described).
IT 9076-57-7, Histone deacetylase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(histone deacetylase inhibitors for treatment of cancer)
RN 9076-57-7 CAPLUS
CN Deacetylase, histone (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
IT 149647-78-9P, SAHA
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(histone deacetylase inhibitors for treatment of cancer)
RN 149647-78-9 CAPLUS
CN Octanediamide, N1-hydroxy-N8-phenyl- (CA INDEX NAME)



IT 382180-17-8, Pyroxamide
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(histone deacetylase inhibitors for treatment of cancer)
RN 382180-17-8 CAPLUS
CN Octanediamide, N1-hydroxy-N8-3-pyridinyl- (CA INDEX NAME)



L42 ANSWER 13 OF 56 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:513346 CAPLUS <<LOGINID::20080505>>
DOCUMENT NUMBER: 141:59733
TITLE: Polymorphs of suberoylanilide hydroxamic acid, method of producing the same, and pharmaceutical composition containing the same
INVENTOR(S): Miller, Thomas A.; Richon, Victoria M.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 60 pp., Cont.-in-part of U.S. Ser. No. 379,149.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 7
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE	
US 20040122101	A1	20040624	US 2003-600132		20030619	<--
US 20040072735	A1	20040415	US 2003-379149		20030304	<--
AU 2007203525	A1	20070816	AU 2007-203525		20070726	
AU 2007203648	A1	20070823	AU 2007-203648		20070803	
PRIORITY APPLN. INFO.:			US 2002-361759P	P	20020304	<--
			US 2003-379149	A2	20030304	
			AU 2003-213684	A3	20030304	
			AU 2004-266169	A3	20040826	

AB The present invention provides methods of selectively inducing terminal differentiation, cell growth arrest and/or apoptosis of neoplastic cells, and/or inhibiting histone deacetylase (HDAC) by administration of pharmaceutical compns. comprising potent HDAC inhibitors. The oral bioavailability of the active compds. in the pharmaceutical compns. of the present invention is surprisingly high. Moreover, the pharmaceutical compns. unexpectedly give rise to high, therapeutically effective blood levels of the active compds. over an extended period of time. The present invention further provides a safe, daily dosing regimen of these pharmaceutical compns., which is easy to follow, and which results in a therapeutically effective amount of the HDAC inhibitors in vivo. The present invention also provides a novel Form I polymorph of SAHA, characterized by a unique X-ray diffraction pattern and Differential Scanning Calorimetry profile, as well a unique crystalline structure.

IT 9076-57-7, Histone deacetylase
RL: BSU (Biological study, unclassified); BIOL (Biological study) (inhibition; polymorphs of suberoylanilide hydroxamic acid, method of producing the same, and pharmaceutical composition containing the same)
RN 9076-57-7 CAPLUS
CN Deacetylase, histone (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
IT 149647-78-9P, Suberoylanilide hydroxamic acid
RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); PKT (Pharmacokinetics); PRP (Properties); PYP (Physical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses) (polymorphs of suberoylanilide hydroxamic acid, method of producing the

same, and pharmaceutical composition containing the same)
RN 149647-78-9 CAPLUS
CN Octanediamide, N1-hydroxy-N8-phenyl- (CA INDEX NAME)



L42 ANSWER 14 OF 56 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:485573 CAPLUS <<LOGINID::20080505>>
DOCUMENT NUMBER: 141:18132
TITLE: Induction of insulin expression by histone deacetylase inhibitors
INVENTOR(S): Levine, Fred; Itkin-Ansari, Pamela
PATENT ASSIGNEE(S): Regents of the University of California, USA
SOURCE: U.S. Pat. Appl. Publ., 16 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20040002447	A1	20040101	US 2002-162952	20020604 <--
WO 2003103613	A2	20031218	WO 2003-US9986	20030401 <--
WO 2003103613	A3	20040401		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003275026	A1	20031222	AU 2003-275026	20030401 <--
EP 1509598	A2	20050302	EP 2003-757244	20030401 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				

PRIORITY APPLN. INFO.: US 2002-162952 A 20020604 <--
WO 2003-US9986 W 20030401

AB The present invention provides comps. and methods for inducing insulin expression in cells by contacting the cells with a histone deacetylase inhibitor. The methods comprise: providing a cell that expresses a PDX-1 or neuroD/BETA2 polynucleotide; and contacting the cell with a histone deacetylase inhibitor, thereby inducing insulin gene expression in the cells. The histone deacetylase inhibitors comprise butyrates, hydroxamic acids, cyclic peptides, benzamides, and GLP-1 receptor agonists.
IT 149647-78-9, Suberoyl anilide hydroxamic acid
RL: BUU (Biological use, unclassified); THU (Therapeutic use);

BIOL (Biological study); USES (Uses)
(induction of insulin expression by histone deacetylase inhibitors)
RN 149647-78-9 CAPLUS
CN Octanediamide, N1-hydroxy-N8-phenyl- (CA INDEX NAME)



IT 9076-57-7, Histone deacetylase
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(inhibitors; induction of insulin expression by histone deacetylase inhibitors)
RN 9076-57-7 CAPLUS
CN Deacetylase, histone (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L42 ANSWER 15 OF 56 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:450591 CAPLUS <<LOGINID::20080505>>
DOCUMENT NUMBER: 141:17644
TITLE: Use of a histone deacetylase inhibitor for the treatment of muscular dystrophies
INVENTOR(S): De la Porte, Sabine; Israel, Maurice; Voisin, Vincent; Haddad, Hafedh
PATENT ASSIGNEE(S): Centre National de la Recherche Scientifique CNRS, Fr.
SOURCE: Fr. Demande, 21 pp.
CODEN: FRXXBL
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2847817	A1	20040604	FR 2002-14980	20021128 <--
FR 2847817	B1	20061110		
CA 2507450	A1	20040617	CA 2003-2507450	20031128 <--
WO 2004050076	A1	20040617	WO 2003-FR3530	20031128 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003294110	A1	20040623	AU 2003-294110	20031128 <--
EP 1565175	A1	20050824	EP 2003-789530	20031128 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				

IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
US 20060148684 A1 20060706 US 2005-536417 20050927 <--
PRIORITY APPLN. INFO.: FR 2002-14980 A 20021128 <--
WO 2003-FR3530 W 20031128

AB The invention discloses the use of an inhibitor of histone deacetylase for the preparation of a drug intended for the treatment or the prevention of a disease resulting from the deficiency of an adult gene by the re-expression of homologous fetal gene. The invention is interested particularly in the treatment of dystrophies, e.g. Duchenne dystrophy or Becker's dystrophy, where the defective adult gene is the dystrophin gene and the homologous fetal gene is the utrophin gene.

IT 9076-57-7, Histone deacetylase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(histone deacetylase inhibitor for treatment of muscular dystrophies)

RN 9076-57-7 CAPLUS

CN Deacetylase, histone (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 149647-78-9, Suberoylanilide hydroxamic acid
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(histone deacetylase inhibitor for treatment of muscular dystrophies)

RN 149647-78-9 CAPLUS

CN Octanediamide, N1-hydroxy-N8-phenyl- (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L42 ANSWER 16 OF 56 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:392325 CAPLUS <<LOGINID::20080505>>
DOCUMENT NUMBER: 140:386067
TITLE: Histone deacetylase (HDAC) inhibitors for the treatment of ocular neovascular or edematous disorders and diseases
INVENTOR(S): Klimko, Peter G.; Bingaman, David P.
PATENT ASSIGNEE(S): Alcon, Inc., Switz.
SOURCE: U.S. Pat. Appl. Publ., 8 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20040092558	A1	20040513	US 2003-697135	20031030 <--
CA 2504460	A1	20040527	CA 2003-2504460	20031030 <--
WO 2004043352	A2	20040527	WO 2003-US34617	20031030 <--
WO 2004043352	A3	20040715		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR

AU 2003287349	A1	20040603	AU 2003-287349			20031030	<--
EP 1560583	A2	20050810	EP 2003-781581			20031030	<--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK							
BR 2003016206	A	20050927	BR 2003-16206			20031030	<--
CN 1711087	A	20051221	CN 2003-80103003			20031030	<--
JP 2006512318	T	20060413	JP 2004-551638			20031030	<--
US 20060074100	A1	20060406	US 2005-531754			20050418	<--
ZA 2005003237	A	20060628	ZA 2005-3237			20050421	<--
IN 2005DN02544	A	20070202	IN 2005-DN2544			20050613	<--
PRIORITY APPLN. INFO.:			US 2002-425574P	P		20021112	<--
			WO 2003-US34617	W		20031030	

OTHER SOURCE(S): MARPAT 140:386067

AB The invention discloses ophthalmic compns. containing HDAC inhibitors and their use for treating ocular neovascular or edematous diseases and disorders.

IT 9076-57-7, Histone deacetylase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(histone deacetylase inhibitors for treatment of ocular neovascular or edematous diseases)

RN 9076-57-7 CAPLUS
CN Deacetylase, histone (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 149647-78-9 329966-97-4 329967-02-4
382180-17-8
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(histone deacetylase inhibitors for treatment of ocular neovascular or edematous diseases)

RN 149647-78-9 CAPLUS
CN Octanediamide, N1-hydroxy-N8-phenyl- (CA INDEX NAME)

RN 329966-97-4 CAPLUS
CN Octanediamide, 2-(benzoylamino)-N8-hydroxy-N1-phenyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 329967-02-4 CAPLUS
CN Octanediamide, 2-(benzoylamino)-N8-hydroxy-N1-8-quinolinyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 382180-17-8 CAPLUS
CN Octanediamide, N1-hydroxy-N8-3-pyridinyl- (CA INDEX NAME)



L42 ANSWER 17 OF 56 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:392299 CAPLUS <<LOGINID::20080505>>
DOCUMENT NUMBER: 140:395534
TITLE: Histone deacetylase inhibitors for treating degenerative diseases of the eye
INVENTOR(S): Hellberg, Peggy E.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 5 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
US 20040092431	A1	20040513	US 2003-694309	20031027	<--
CA 2504226	A1	20040527	CA 2003-2504226	20031027	<--
WO 2004043348	A2	20040527	WO 2003-US33873	20031027	<--
WO 2004043348	A3	20040715			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR					
AU 2003286686	A1	20040603	AU 2003-286686	20031027	<--
EP 1562592	A2	20050817	EP 2003-777895	20031027	<--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
BR 2003016163	A	20050927	BR 2003-16163	20031027	<--
CN 1711086	A	20051221	CN 2003-80102935	20031027	<--
JP 2006508120	T	20060309	JP 2004-551572	20031027	<--
US 20070088045	A1	20070419	US 2005-531747	20050418	<--
ZA 2005003230	A	20060628	ZA 2005-3230	20050421	<--
MX 2005PA04738	A	20050803	MX 2005-PA4738	20050503	<--
US 20080004311	A1	20080103	US 2007-836309	20070809	<--
IN 2007DN07459	A	20071109	IN 2007-DN7459	20070927	<--
PRIORITY APPLN. INFO.:			US 2002-425576P	P 20021112	<--
			US 2003-694309	A2 20031027	
			WO 2003-US33873	W 20031027	
			IN 2005-DN2543	A3 20050613	

AB Compns. and methods for treating degenerative conditions and diseases of the eye with histone deacetylase inhibitors are disclosed.

IT 149647-78-9, Suberoylanilide hydroxamic acid
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(histone deacetylase inhibitors for treating degenerative diseases of the eye)

RN 149647-78-9 CAPLUS

CN Octanediamide, N1-hydroxy-N8-phenyl- (CA INDEX NAME)



IT 9076-57-7, Histone deacetylase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; histone deacetylase inhibitors for treating degenerative diseases of the eye)

RN 9076-57-7 CAPLUS

CN Deacetylase, histone (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L42 ANSWER 18 OF 56 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:372881 CAPLUS <<LOGINID::20080505>>
DOCUMENT NUMBER: 140:368663
TITLE: Methods of treating cancer with hydroxamic acid derivative histone deacetylase (HDAC) inhibitors
INVENTOR(S): Bacopoulos, Nicholas G.; Chiao, Judy H.; Miller, Thomas A.; Paradise, Carolyn M.; Richon, Victoria M.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 45 pp., Cont.-in-part of U.S. Ser. No. 379,149.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 7
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
US 20040087631	A1	20040506	US 2003-650025	20030826	<--
US 7148257	B2	20061212			
US 20040072735	A1	20040415	US 2003-379149	20030304	<--
AU 2004266169	A1	20050303	AU 2004-266169	20040826	
AU 2004266169	A2	20060406			
AU 2004266169	B2	20070503			
AU 2004266169	B9	20070510			
CA 2535806	A1	20050303	CA 2004-2535806	20040826	
WO 2005018578	A2	20050303	WO 2004-US27943	20040826	
WO 2005018578	A3	20050512			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
EP 1663194	A2	20060607	EP 2004-782425	20040826	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK					
BR 2004013826	A	20061024	BR 2004-13826	20040826	
CN 1870985	A	20061129	CN 2004-80031306	20040826	
JP 2007518694	T	20070712	JP 2006-524891	20040826	
KR 2007029617	A	20070314	KR 2006-703748	20060224	
MX 2006PA02234	A	20060801	MX 2006-PA2234	20060227	
NO 2006001348	A	20060523	NO 2006-1348	20060324	
US 20060167103	A1	20060727	US 2006-391971	20060328	<--
US 20070060614	A1	20070315	US 2006-567952	20061117	<--
AU 2007203525	A1	20070816	AU 2007-203525	20070726	
AU 2007203648	A1	20070823	AU 2007-203648	20070803	
PRIORITY APPLN. INFO.:			US 2002-361759P	P 20020304	<--
			US 2003-379149	A2 20030304	

AU 2003-213684	A3	20030304
US 2003-650025	A	20030826
US 2003-665079	A	20030916
AU 2004-266169	A3	20040826
WO 2004-US27943	W	20040826

OTHER SOURCE(S): MARPAT 140:368663

AB The invention provides methods for treating cancers (e.g. mesothelioma), chemoprevention, selectively inducing terminal differentiation, cell growth arrest and/or apoptosis of neoplastic cells, and/or inhibiting histone deacetylase (HDAC) by administration of pharmaceutical compns. comprising potent HDAC inhibitors. The oral bioavailability of the active compds. in the pharmaceutical compns. of the invention is surprisingly high. Moreover, the pharmaceutical compns. unexpectedly give rise to high, therapeutically effective blood levels of the active compds. over an extended period of time. The invention further provides a safe, daily dosing regimen of these pharmaceutical compns., which is easy to follow, and which results in a therapeutically effective amount of the HDAC inhibitors in vivo. HDAC inhibitors of the invention are hydroxamic acid derivs. e.g. suberoylanilide hydroxamic acid (SAHA; preparation described).

IT 9076-57-7, Histone deacetylase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(hydroxamic acid derivative histone deacetylase inhibitors for treatment of cancer)

RN 9076-57-7 CAPLUS

CN Deacetylase, histone (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 149647-78-9P, Suberoylanilide hydroxamic acid
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(hydroxamic acid derivative histone deacetylase inhibitors for treatment of cancer)

RN 149647-78-9 CAPLUS

CN Octanediamide, N1-hydroxy-N8-phenyl- (CA INDEX NAME)

IT 382180-17-8, Pyroxamide
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(hydroxamic acid derivative histone deacetylase inhibitors for treatment of cancer)

RN 382180-17-8 CAPLUS

CN Octanediamide, N1-hydroxy-N8-3-pyridinyl- (CA INDEX NAME)



REFERENCE COUNT: 185 THERE ARE 185 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L42 ANSWER 19 OF 56 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:310834 CAPLUS <<LOGINID::20080505>>
DOCUMENT NUMBER: 140:339332
TITLE: Preparation of trisubstituted dioxanes as histone deacetylase inhibitors.
INVENTOR(S): Schreiber, Stuart L.; Sternson, Scott M.; Wong, Jason C.; Grozinger, Christina M.; Haggarty, Stephen J.; Koeller, Kathryn M.
PATENT ASSIGNEE(S): President and Fellows of Harvard College, USA
SOURCE: U.S. Pat. Appl. Publ., 177 pp., Cont.-in-part of U.S. Pat. Appl. 2003 187,027.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE	
US 20040072849	A1	20040415	US 2003-621276		20030717	<--
US 7244853	B2	20070717				
US 20030187027	A1	20031002	US 2002-144316		20020509	<--
PRIORITY APPLN. INFO.:			US 2001-289850P	P	20010509	<--
			US 2002-144316	A2	20020509	<--

OTHER SOURCE(S): MARPAT 140:339332
GI



AB Title compds. [I; R1, Y = H, aliphatyl, alicyclyl, heteroaliphatyl, heterocyclyl, aryl, heteroaryl; n = 1-5; R2 = R1, protecting group; X = O, S, C(R2a)2, NR2a; R2R2a = atoms to form alicyclyl, heterocyclyl, aryl,

heteroaryl; R3 = aliphatyl, alicyclyl, heteroaliphatyl, heterocyclyl, aryl, heteroaryl], were claimed. Thus, rel-N-[4-[(2R,4R,6S)-4-[[(4,5-diphenyl-2-oxazolyl)thio]methyl]-6-[4-(hydroxymethyl)phenyl]-1,3-dioxan-2-yl]phenyl]-N'-hydroxy-octanediamide (tubacin, claimed compound) at ≥125 nM in A549 cells strongly increased α-tubulin acetylation levels. The present invention addnl. provides methods for modulating the glucose-sensitive subset of genes downstream of Ure2p.

IT 537049-40-4P, Tubacin
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(claimed compound; preparation of trisubstituted dioxanes as histone deacetylase inhibitors)

RN 537049-40-4 CAPLUS

CN Octanediamide, N1-[4-[(2R,4R,6S)-4-[[(4,5-diphenyl-2-oxazolyl)thio]methyl]-6-[4-(hydroxymethyl)phenyl]-1,3-dioxan-2-yl]phenyl]-N8-hydroxy-, rel- (CA INDEX NAME)

Relative stereochemistry.



IT 9076-57-7, Histone deacetylase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors, HDAC1 or HDAC6; preparation of trisubstituted dioxanes as histone deacetylase inhibitors)

RN 9076-57-7 CAPLUS

CN Deacetylase, histone (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 438496-81-2, Tubulin deacetylase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; preparation of trisubstituted dioxanes as histone deacetylase inhibitors)

RN 438496-81-2 CAPLUS

CN Deacetylase, nicotinamide adenine dinucleotide-dependent protein (CA

INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
IT 394657-69-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of trisubstituted dioxanes as histone deacetylase inhibitors)
RN 394657-69-3 CAPLUS
CN Octanediamide, N-[3-[(2R,4R,6S)-4-[(2-benzothiazolylthio)methyl]-6-[4-(hydroxymethyl)phenyl]-1,3-dioxan-2-yl]phenyl]-N'-hydroxy-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L42 ANSWER 20 OF 56 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:269998 CAPLUS <<LOGINID::20080505>>
DOCUMENT NUMBER: 140:247047
TITLE: Method of treating leukemia with a combination of suberoylanilide hydroxamic acid and imatinib mesylate
INVENTOR(S): Bhalla, Kapil N.; Nimmanapalli, Ramedevi
PATENT ASSIGNEE(S): University of South Florida, USA
SOURCE: PCT Int. Appl., 12 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004026234	A2	20040401	WO 2003-US28964	20030919 <--
WO 2004026234	A3	20040708		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,

LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN,
TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2499189	A1	20040401	CA 2003-2499189	20030919	<--
AU 2003270668	A1	20040408	AU 2003-270668	20030919	<--
US 20040127571	A1	20040701	US 2003-605283	20030919	<--
EP 1545536	A2	20050629	EP 2003-752375	20030919	<--

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

PRIORITY APPLN. INFO.:	US 2002-319563P	P	20020919 <--
	US 2003-605283	A	20030919
	WO 2003-US28964	W	20030919

AB The invention discloses a method for inducing apoptosis, or increasing the rate or extent of apoptosis, in target cells. The method comprises contacting the cancer cells with an apoptosis-inducing amount of a tyrosine kinase inhibitor, imatinib mesylate, and a histone deacetylase inhibitor, suberoylanilide Hydroxamic Acid (SAHA). The method is applicable to ameliorating the resistance of the accelerated and blast phases of CML (CML-BC) to imatinib mesylate.

IT 9076-57-7, Histone deacetylase
RL: BSU (Biological study, unclassified); BIOL (Biological study) (inhibitors; suberoylanilide hydroxamic acid-imatinib mesylate combination for leukemia treatment)
RN 9076-57-7 CAPLUS
CN Deacetylase, histone (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
IT 149647-78-9, Suberoylanilide hydroxamic acid
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(suberoylanilide hydroxamic acid-imatinib mesylate combination for leukemia treatment)
RN 149647-78-9 CAPLUS
CN Octanediamide, N1-hydroxy-N8-phenyl- (CA INDEX NAME)



L42 ANSWER 21 OF 56 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER:	2004:252351 CAPLUS <<LOGINID::20080505>>
DOCUMENT NUMBER:	140:264488
TITLE:	Combination of a benzamide derivative and a histone deacetylase inhibitor for the treatment of leukemia
INVENTOR(S):	Dent, Paul; Grant, Steven; Krystal, Geoffrey; Yu, Chunrong
PATENT ASSIGNEE(S):	Virginia Commonwealth University, USA; Mcguire Va Medical Center 111k

SOURCE: PCT Int. Appl., 37 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004024160	A1	20040325	WO 2003-IB4053	20030910 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SE, SG, SK, SY, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW				
RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR				
CA 2498210	A1	20040325	CA 2003-2498210	20030910 <--
AU 2003259521	A1	20040430	AU 2003-259521	20030910 <--
BR 2003014112	A	20050712	BR 2003-14112	20030910 <--
EP 1553948	A1	20050720	EP 2003-795175	20030910 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1681505	A	20051012	CN 2003-821763	20030910 <--
JP 2006501267	T	20060112	JP 2004-535791	20030910 <--
US 20060100140	A1	20060511	US 2005-527553	20050909 <--
PRIORITY APPLN. INFO.:			US 2002-410286P P	20020913 <--
			US 2002-411344P P	20020918 <--
			WO 2003-IB4053 W	20030910

AB The invention pertains to a combination of a histone deacetylase inhibitor and N-[5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl]-4-(3-pyridyl)-2-pyrimidine (I) or a pharmaceutically acceptable salt thereof for simultaneous, sep. or sequential use for the treatment of leukemia and especially Compound I-resistant leukemia. The histone deacetylase inhibitor is selected from sodium butyrate, MS 275, SAHA, aphacidin, depsipeptide, FK 228, trichostatin A, etc. For example, exposure of K562 cells for 24 h to Compound I concns. as high as 300 nM negibly induced apoptosis, while 2.0 μM SAHA administered alone was also minimally toxic. However, when cells were exposed to SAHA in combination with 100 nM Compound I, a clear increase in apoptosis was observed (i.e., .apprx.20%), and for Compound I concentration of 250 nM, the large majority of cells (i.e., .apprx.75%) were apoptotic. Median Dose Effect anal. of apoptosis induction over a range of Compound I and SAHA concns. yielded Combination Index (CI) values lower than 1.0, corresponding to a synergistic interaction.

IT 149647-78-9, SAHA
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination of histone deacetylase inhibitor and antitumor benzamide derivative for treatment of leukemia)

RN 149647-78-9 CAPLUS
CN Octanediamide, N1-hydroxy-N8-phenyl- (CA INDEX NAME)

IT 9076-57-7, Histone deacetylase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; combination of histone deacetylase inhibitor and antitumor benzamide derivative for treatment of leukemia)
RN 9076-57-7 CAPLUS
CN Deacetylase, histone (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L42 ANSWER 22 OF 56 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:182726 CAPLUS <<LOGINID::20080505>>
DOCUMENT NUMBER: 140:229435
TITLE: Arthrodial cartilage extracellular matrix degradation inhibitor
INVENTOR(S): Yamaji, Noboru; Shindou, Nobuaki; Terada, Yoh
PATENT ASSIGNEE(S): Yamanouchi Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 25 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004017996	A1	20040304	WO 2003-JP10460	20030819 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2495354	A1	20040304	CA 2003-2495354	20030819 <--
AU 2003254951	A1	20040311	AU 2003-254951	20030819 <--
EP 1547617	A1	20050629	EP 2003-792716	20030819 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 20050272647	A1	20051208	US 2005-525015	20050217 <--
PRIORITY APPLN. INFO.:			JP 2002-239203 A	20020820 <--
			WO 2003-JP10460 W	20030819

AB An arthrodial cartilage extracellular matrix degradation inhibitor, which contains a compound inhibiting histone deacetylase as the active ingredient, is useful in preventing and treating diseases and pathol. conditions in which the degradation and denaturation of arthrodial cartilage extracellular

matrix participate, in particular, osteoarthritis, articular rheumatism, arthritis deformans, etc.
IT 9076-57-7, Histone deacetylase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(arthrodial cartilage extracellular matrix degradation inhibitor)
RN 9076-57-7 CAPLUS
CN Deacetylase, histone (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
IT 149647-78-9, SAHA
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(arthrodial cartilage extracellular matrix degradation inhibitor)
RN 149647-78-9 CAPLUS
CN Octanediamide, N1-hydroxy-N8-phenyl- (CA INDEX NAME)



REFERENCE COUNT: 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L42 ANSWER 23 OF 56 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:117798 CAPLUS <<LOGINID::20080505>>
DOCUMENT NUMBER: 140:139491
TITLE: BCR-ABL tyrosine kinase and histone deacetylase inhibitors as antitumor agents for treatment of chronic myelocytic leukemia and PH-pos. acute lymphoid leukemia
INVENTOR(S): Karato, Masayuki
PATENT ASSIGNEE(S): Nagoya Industrial Science Research Institute, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 17 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2004043390	A	20040212	JP 2002-204889	20020712 <--
PRIORITY APPLN. INFO.:			JP 2002-204889	20020712 <--

AB BCR-ABL tyrosine kinase inhibitors, including imatinib mesylate, and histone deacetylase inhibitors, e.g. valproic acid, phenylbutyrate, SAHA, FR901228, MS 27275, and CHAPs, are claimed as antitumor agents for treatment of chronic myelocytic leukemia and PH-pos. acute lymphoid leukemia. The two enzyme inhibitors had synergistic antitumor actions with each others.
IT 9076-57-7, Histone deacetylase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(BCR-ABL tyrosine kinase and histone deacetylase inhibitors as antitumor agents for treatment of chronic myelocytic leukemia and

PH-pos. acute lymphoid leukemia)
RN 9076-57-7 CAPLUS
CN Deacetylase, histone (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
IT 149647-78-9, SAHA
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(BCR-ABL tyrosine kinase and histone deacetylase inhibitors as antitumor agents for treatment of chronic myelocytic leukemia and PH-pos. acute lymphoid leukemia)
RN 149647-78-9 CAPLUS
CN Octanediamide, N1-hydroxy-N8-phenyl- (CA INDEX NAME)



L42 ANSWER 24 OF 56 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:80835 CAPLUS <<LOGINID::20080505>>
DOCUMENT NUMBER: 140:151933
TITLE: Stents capable of controllably releasing histone deacetylase inhibitors
INVENTOR(S): Tseng, Xufan; Xu, Shuyun
PATENT ASSIGNEE(S): Advanced Stent Technologies, Inc., USA
SOURCE: PCT Int. Appl., 73 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004009771	A2	20040129	WO 2003-US22449	20030718 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003249309	A1	20040209	AU 2003-249309	20030718 <--
PRIORITY APPLN. INFO.:			US 2002-397780P	P 20020724 <--
			US 2002-402086P	P 20020809 <--
			WO 2003-US22449	W 20030718

AB A stent device includes a stent body and one or more HDAC inhibitor depot(s) provided on or in the stent body, the depot(s) capable of controllably releasing HDAC inhibitor(s). Methods of using the stents in

treating and/or preventing restenosis are provided. A delivery system including the stent device and a methods of using the delivery system in treating and/or preventing restenosis are also provided. Kits comprising stents are provided. Trichostatin A inhibited human aortic SMC proliferation in vitro in a dose-dependent manner.

IT 9076-57-7, Histone deacetylase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(stents capable of controllably releasing histone deacetylase inhibitors)

RN 9076-57-7 CAPLUS
CN Deacetylase, histone (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 149647-78-9, SAHA 382180-17-8, Pyroxamide
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(stents capable of controllably releasing histone deacetylase inhibitors)

RN 149647-78-9 CAPLUS
CN Octanediamide, N1-hydroxy-N8-phenyl- (CA INDEX NAME)



RN 382180-17-8 CAPLUS
CN Octanediamide, N1-hydroxy-N8-3-pyridinyl- (CA INDEX NAME)



L42 ANSWER 25 OF 56 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2003:855790 CAPLUS <<LOGINID::20080505>>
DOCUMENT NUMBER: 139:345907
TITLE: Combination therapy for the treatment of cancer using histone deacetylase inhibitors and radiotherapy
INVENTOR(S): Sgouros, George; Richon, Victoria M.; Marks, Paul A.; Rifkind, Richard A.
PATENT ASSIGNEE(S): Sloan-Kettering Institute for Cancer Research, USA
SOURCE: PCT Int. Appl., 94 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003088954	A1	20031030	WO 2003-US11812	20030415 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2482508	A1	20031030	CA 2003-2482508	20030415 <--
AU 2003226408	A1	20031103	AU 2003-226408	20030415 <--
AU 2003226408	B2	20070614		
US 20040018968	A1	20040129	US 2003-413422	20030415 <--
EP 1501489	A1	20050202	EP 2003-747011	20030415 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003009280	A	20050222	BR 2003-9280	20030415 <--
JP 2005530734	T	20051013	JP 2003-585706	20030415 <--
CN 1728991	A	20060201	CN 2003-813849	20030415 <--
MX 2004PA10199	A	20050705	MX 2004-PA10199	20041015 <--
IN 2006DN07048	A	20070713	IN 2006-DN7048	20061123 <--
PRIORITY APPLN. INFO.:			US 2002-373033P P	20020415 <--
			WO 2003-US11812 W	20030415
			IN 2004-DN3312 A3	20041026

OTHER SOURCE(S): MARPAT 139:345907

AB The present invention relates to a method for the treatment of cancer in a patient in need thereof. The method comprises administering to a patient in need thereof a first amount of a histone deacetylase inhibitor in a first treatment procedure, and a second amount or dose of radiation in a second treatment procedure. The first and second treatments together comprise a therapeutically effective amount The combination of the HDAC inhibitor and radiation therapy is therapeutically synergistic.

IT 9076-57-7, Histone deacetylase
RL: BSU (Biological study, unclassified); BIOL (Biological study) (combination therapy for treatment of cancer using histone deacetylase inhibitors and radiotherapy)
RN 9076-57-7 CAPLUS
CN Deacetylase, histone (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 149647-78-9, SAHA 382180-17-8, Pyroxamide
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination therapy for treatment of cancer using histone deacetylase inhibitors and radiotherapy)
RN 149647-78-9 CAPLUS
CN Octanediamide, N1-hydroxy-N8-phenyl- (CA INDEX NAME)



RN 382180-17-8 CAPLUS
CN Octanediamide, N1-hydroxy-N8-3-pyridinyl- (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L42 ANSWER 26 OF 56 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2003:796863 CAPLUS <<LOGINID::20080505>>
DOCUMENT NUMBER: 139:286376
TITLE: Histone deacetylase inhibitors for the treatment of multiple sclerosis, amyotrophic lateral sclerosis and Alzheimer's disease
INVENTOR(S): Dangond, Fernando
PATENT ASSIGNEE(S): Brigham and Women's Hospital, Inc., USA
SOURCE: PCT Int. Appl., 57 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003083067	A2	20031009	WO 2003-US9273	20030327 <--
WO 2003083067	A8	20040819		
WO 2003083067	A3	20050324		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003226014	A1	20031013	AU 2003-226014	20030327 <--
US 20040077591	A1	20040422	US 2003-401274	20030327 <--
PRIORITY APPLN. INFO.:			US 2002-368228P P	20020328 <--
			US 2002-404664P P	20020820 <--
			WO 2003-US9273 W	20030327

AB The present invention provide therapies for Alzheimer's disease (AD), multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS). The method relies on the use of an HDAC inhibitor, alone or in combination with other drugs, to prevent or treat AD, MS or ALS. Also provided are

methods of screening for addnl. HDAC inhibitors with particular efficacy against these disease states. Modulation of expression of genes, involved in neuroprotection and immune regulation, by HDAC inhibitors were demonstrated.

IT 149647-78-9, Suberoylanilide hydroxamic acid 382180-17-8
, Pyroxamide
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(HDAC inhibitor; histone deacetylase inhibitors for treatment of multiple sclerosis, amyotrophic lateral sclerosis and Alzheimer's disease)

RN 149647-78-9 CAPLUS
CN Octanediamide, N1-hydroxy-N8-phenyl- (CA INDEX NAME)



RN 382180-17-8 CAPLUS
CN Octanediamide, N1-hydroxy-N8-3-pyridinyl- (CA INDEX NAME)



IT 9076-57-7, Histone deacetylase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; histone deacetylase inhibitors for treatment of multiple sclerosis, amyotrophic lateral sclerosis and Alzheimer's disease)

RN 9076-57-7 CAPLUS
CN Deacetylase, histone (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L42 ANSWER 27 OF 56 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2003:737519 CAPLUS <<LOGINID::20080505>>
DOCUMENT NUMBER: 139:240347
TITLE: Methods of inducing terminal differentiation
INVENTOR(S): Richon, Victoria M.
PATENT ASSIGNEE(S): Aton Pharma, Inc., USA
SOURCE: PCT Int. Appl., 91 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 7
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003075839	A2	20030918	WO 2003-US6451	20030304 <--
WO 2003075839	A3	20031231		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2478094	A1	20030918	CA 2003-2478094	20030304 <--
AU 2003213684	A1	20030922	AU 2003-213684	20030304 <--
AU 2003213684	B2	20070426		
EP 1487426	A2	20041222	EP 2003-711372	20030304 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003008250	A	20050111	BR 2003-8250	20030304 <--
JP 2005525369	T	20050825	JP 2003-574115	20030304 <--
CN 1720034	A	20060111	CN 2003-809589	20030304 <--
RU 2320331	C2	20080327	RU 2004-133675	20030304 <--
NZ 535578	A	20080328	NZ 2003-535578	20030304 <--
MX 2004PA08577	A	20050713	MX 2004-PA8577	20040903 <--
NO 2004004112	A	20041130	NO 2004-4112	20040928 <--
ZA 2004007942	A	20060531	ZA 2004-7942	20060314 <--
KR 2007057794	A	20070607	KR 2007-703262	20070209 <--
IN 2007DN05143	A	20070831	IN 2007-DN5143	20070703 <--
AU 2007203525	A1	20070816	AU 2007-203525	20070726
AU 2007203648	A1	20070823	AU 2007-203648	20070803

PRIORITY APPLN. INFO.:	US 2002-361759P	P	20020304 <--
	AU 2003-213684	A3	20030304
	WO 2003-US6451	W	20030304
	AU 2004-266169	A3	20040826
	KR 2004-713883	A3	20040904
	IN 2004-DN2721	A3	20040915

OTHER SOURCE(S): MARPAT 139:240347

AB The present invention provides methods of selectively inducing terminal differentiation, cell growth arrest and/or apoptosis of neoplastic cells, and/or inhibiting histone deacetylase (HDAC) by administration of pharmaceutical compns. comprising potent HDAC inhibitors. The oral bioavailability of the active compds. such as such as suberoylanilide hydroxamic acid (SAHA) in the pharmaceutical compns. of the present invention is surprisingly high. Moreover, the pharmaceutical compns. unexpectedly give rise to high, therapeutically effective blood levels of the active compds. over an extended period of time. The present invention further provides a safe, daily dosing regimen of these pharmaceutical compns., which is easy to follow, and which results in a therapeutically effective amount of the HDAC inhibitors in vivo.

IT 9076-57-7, Histone deacetylase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(methods of inducing terminal differentiation of neoplastic cells using histone deacetylase inhibitors such as suberoylanilide hydroxamic acid with good bioavailability)

RN 9076-57-7 CAPLUS
CN Deacetylase, histone (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
IT 149647-78-9P, Suberoylanilide hydroxamic acid
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(methods of inducing terminal differentiation of neoplastic cells using histone deacetylase inhibitors such as suberoylanilide hydroxamic acid with good bioavailability)
RN 149647-78-9 CAPLUS
CN Octanediamide, N1-hydroxy-N8-phenyl- (CA INDEX NAME)



IT 382180-17-8, Pyroxamide
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(methods of inducing terminal differentiation of neoplastic cells using histone deacetylase inhibitors such as suberoylanilide hydroxamic acid with good bioavailability)
RN 382180-17-8 CAPLUS
CN Octanediamide, N1-hydroxy-N8-3-pyridinyl- (CA INDEX NAME)



L42 ANSWER 28 OF 56 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2003:473272 CAPLUS <<LOGINID::20080505>>
DOCUMENT NUMBER: 139:47148
TITLE: Method of treating autoimmune diseases
INVENTOR(S): Kammer, Gary M.; Mishra, Nilamadhab
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 40 pp., Cont.-in-part of U.S. Ser. No. 718,195.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

US 20030114525	A1	20030619	US 2002-151481	20020520 <--
US 7271198	B2	20070918		
WO 2002055017	A2	20020718	WO 2001-US43871	20011119 <--
WO 2002055017	A3	20030123		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 20060030626	A1	20060209	US 2005-237245	20050928 <--
US 20060178437	A1	20060810	US 2006-403608	20060413 <--
PRIORITY APPLN. INFO.:			US 2000-718195	B2 20001120 <--
			WO 2001-US43871	A 20011119 <--
			US 2002-151481	A3 20020520 <--
			US 2002-187586	A3 20020702 <--

OTHER SOURCE(S): MARPAT 139:47148

AB A method of treating an autoimmune disease comprising administering to the subject a treatment effective amount of a histone hyperacetylating agent, or a pharmaceutically acceptable salt thereof.

IT 9076-57-7, Histone deacetylase
RL: BSU (Biological study, unclassified); BIOL (Biological study) (inhibitor; method of treating autoimmune diseases using a histone hyperacetylating agent)

RN 9076-57-7 CAPLUS

CN Deacetylase, histone (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 149647-78-9, Suberoylanilide Hydroxamic acid
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (method of treating autoimmune diseases using a histone hyperacetylating agent)

RN 149647-78-9 CAPLUS

CN Octanediamide, N1-hydroxy-N8-phenyl- (CA INDEX NAME)



REFERENCE COUNT: 81 THERE ARE 81 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L42 ANSWER 29 OF 56 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2003:335262 CAPLUS <<LOGINID::20080505>>

DOCUMENT NUMBER: 138:349698

TITLE: Screening system for modulators of gene HER2 (neu/ErbB2) transcription, HER2 modulators identified thereby, and methods involving HER2 SNPs

INVENTOR(S): Benz, Christopher C.
PATENT ASSIGNEE(S): Buck Institute for Age Research, USA
SOURCE: PCT Int. Appl., 103 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003035843	A2	20030501	WO 2002-US34288	20021025 <--
WO 2003035843	A3	20040826		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002353891	A1	20030506	AU 2002-353891	20021025 <--
US 20050123896	A1	20050609	US 2004-493141	20041025 <--
PRIORITY APPLN. INFO.:			US 2001-346262P P	20011025 <--
			US 2001-335290P P	20011130 <--
			US 2002-374161P P	20020417 <--
			WO 2002-US34288 W	20021025 <--

AB This invention pertains to the development of a screening system to identify (screen for) gene HER2 (neu/ErbB2) promoter silencing agents. Such agents are expected to be of therapeutic value in the treatment of cancers characterized by HER2 amplification/upregulation. In addition, this invention pertains to the discovery that histone deacetylase (HDAC) inhibitors like sodium butyrate and trichostatin A (TSA), in a time and dose dependent fashion can silence genomically integrated and/or amplified/overexpressing promoters, such as that driving the HER2 (neu/ErbB2) oncogene, resulting in inhibition of gene products including transcripts and protein, and subsequent production of tumor/cell growth inhibition, apoptosis and/or differentiation. In another embodiment, this invention provides novel single nucleotide polymorphisms (SNPs) associated with the coding region of the HER2 proto-oncogene. The SNPs are indicators for altered risk, for developing ErbB2-pos. cancer in a mammal.

IT 149647-78-9, SAHA
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(histone deacetylase inhibitor; screening system for modulators of gene HER2 (neu/ErbB2) transcription and HER2 modulators identified thereby)

RN 149647-78-9 CAPLUS

CN Octanediamide, N1-hydroxy-N8-phenyl- (CA INDEX NAME)



IT 9076-57-7, Histone deacetylase
RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(inhibitor; screening system for modulators of gene HER2 (neu/ErbB2) transcription and HER2 modulators identified thereby)
RN 9076-57-7 CAPLUS
CN Deacetylase, histone (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L42 ANSWER 30 OF 56 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2003:319660 CAPLUS <<LOGINID::20080505>>
DOCUMENT NUMBER: 138:314634
TITLE: Use of a histone deacetylase (HDAC) inhibitor for the treatment of neurodegenerative diseases and cancer of the brain
INVENTOR(S): Richon, Victoria M.; Marks, Paul A.; Rifkind, Richard A.
PATENT ASSIGNEE(S): Sloan-Kettering Institute for Cancer Research, USA
SOURCE: PCT Int. Appl., 88 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003032921	A2	20030424	WO 2002-US33246	20021016 <--
WO 2003032921	A3	20031030		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2463552	A1	20030424	CA 2002-2463552	20021016 <--
AU 2002340253	A1	20030428	AU 2002-340253	20021016 <--
US 20040087657	A1	20040506	US 2002-273401	20021016 <--
EP 1443928	A2	20040811	EP 2002-778601	20021016 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
JP 2005506348	T	20050303	JP 2003-535727	20021016 <--
US 20060079551	A1	20060413	US 2005-282420	20051118 <--
AU 2006200326	A1	20060216	AU 2006-200326	20060125 <--
PRIORITY APPLN. INFO.:			US 2001-329705P	P 20011016 <--
			AU 2002-340253	A3 20021016 <--
			US 2002-273401	A3 20021016 <--
			WO 2002-US33246	W 20021016 <--

OTHER SOURCE(S): MARPAT 138:314634
AB A method is provided for inhibiting HDAC in the brain of a mammal. The

method comprises administering to a mammal a HDAC inhibiting amount of a histone deacetylase inhibitor compound Also provided is a method for treating diseases of the central nervous system (CNS) comprising administering a therapeutically effective amount of an inhibitor of HDAC. In particular embodiments, the CNS disease is a neurodegenerative disease. In further embodiments, the neurodegenerative disease is an inherited neurodegenerative disease, such as those inherited neurodegenerative diseases which are polyglutamine expansion diseases. In other embodiments, the disorder is cancer of the brain. The individual is a mammal, e.g. a primate or human.

IT 9076-57-7, Histone deacetylase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(histone deacetylase inhibitor for treatment of neurodegenerative diseases and brain cancer)

RN 9076-57-7 CAPLUS
CN Deacetylase, histone (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 149647-78-9 329966-68-9 329966-92-9
329966-97-4 329966-98-5 329967-00-2
329967-01-3 329967-02-4 382180-17-8
512170-05-7
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(histone deacetylase inhibitor for treatment of neurodegenerative diseases and brain cancer)

RN 149647-78-9 CAPLUS
CN Octanediamide, N1-hydroxy-N8-phenyl- (CA INDEX NAME)



RN 329966-68-9 CAPLUS
CN 1,1,6-Hexanetricarboxamide, N6-hydroxy-N1,N1'-di-8-quinolinyl- (9CI) (CA INDEX NAME)



RN 329966-92-9 CAPLUS
CN 1,1,6-Hexanetricarboxamide, N6-hydroxy-N1,N1'-di-6-quinolinyl- (9CI) (CA INDEX NAME)



RN 329966-97-4 CAPLUS
CN Octanediamide, 2-(benzoylamino)-N8-hydroxy-N1-phenyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 329966-98-5 CAPLUS
CN Octanediamide, N8-hydroxy-N1-phenyl-2-[(3-pyridinylcarbonyl)amino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 329967-00-2 CAPLUS
CN Carbamic acid, N-[(1S)-7-(hydroxyamino)-7-oxo-1-[(phenylamino)carbonyl]heptyl]-, phenylmethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 329967-01-3 CAPLUS
CN Carbamic acid, N-[(1S)-7-(hydroxyamino)-7-oxo-1-[(8-quinolinylamino)carbonyl]heptyl]-, phenylmethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 329967-02-4 CAPLUS
CN Octanediamide, 2-(benzoylamino)-N8-hydroxy-N1-8-quinolinyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 382180-17-8 CAPLUS
CN Octanediamide, N1-hydroxy-N8-3-pyridinyl- (CA INDEX NAME)



RN 512170-05-7 CAPLUS
CN 1,1,6-Hexanetricarboxamide, N6-hydroxy-N1,N1'-di-3-quinolinyl- (9CI) (CA INDEX NAME)



L42 ANSWER 31 OF 56 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2003:259705 CAPLUS <<LOGINID::20080505>>
DOCUMENT NUMBER: 138:292737
TITLE: Inhibition of histone deacetylase as a treatment for cardiac hypertrophy
INVENTOR(S): Bristow, Michael R.; Long, Carlin; McKinsey, Timothy A.; Olson, Eric N.
PATENT ASSIGNEE(S): Board of Regents, the University of Texas System, USA; The Regents of the University of Colorado
SOURCE: Eur. Pat. Appl., 39 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1297851	A1	20030402	EP 2002-21676	20020927 <--
EP 1297851	B1	20050126		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
US 20030144340	A1	20030731	US 2002-256221	20020926 <--
US 6706686	B2	20040316		
JP 2003238445	A	20030827	JP 2002-284313	20020927 <--
AT 287731	T	20050215	AT 2002-21676	20020927 <--
PT 1297851	T	20050630	PT 2002-21676	20020927 <--
ES 2236415	T3	20050716	ES 2002-21676	20020927 <--
EP 1605262	A1	20051214	EP 2005-1443	20020927 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR, BG, CZ, EE, SK				

US 20040186049	A1	20040923	US 2004-801985		20040316 <--
US 6946441	B2	20050920			
US 20060025333	A1	20060202	US 2005-190074		20050726 <--
US 20060069014	A1	20060330	US 2005-215844		20050830 <--
PRIORITY APPLN. INFO.:			US 2001-325311P	P	20010927 <--
			US 2001-334041P	P	20011031 <--
			US 2002-256221	A1	20020926 <--
			EP 2002-21676	A3	20020927 <--
			US 2004-801985	A1	20040316
			US 2005-190074	A1	20050726

AB The present invention provides for methods of treating and preventing cardiac hypertrophy. Class II HDACs, which are known to participate in regulation of chromatin structure and gene expression, have been shown to have beneficial effects on cardiac hypertrophy. Surprisingly, the present invention demonstrates that HDAC inhibitors inhibit cardiac hypertrophy by inhibiting fetal cardiac gene expression and interfering with sarcomeric organization. Inhibitors include trichostatin A, trapoxin B, MS 275-27, m-carboxycinnamic acid bis-hydroxamide, depudecin, oxamflatin, apicidin, suberoylanilide hydroxamic acid, Scriptaid, etc.

IT 149647-78-9, Suberoylanilide hydroxamic acid 382180-17-8 , Pyroxamide
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(inhibition of histone deacetylase as a treatment for cardiac hypertrophy)

RN 149647-78-9 CAPLUS
CN Octanediamide, N1-hydroxy-N8-phenyl- (CA INDEX NAME)



RN 382180-17-8 CAPLUS
CN Octanediamide, N1-hydroxy-N8-3-pyridinyl- (CA INDEX NAME)



IT 9076-57-7, Histone deacetylase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; inhibition of histone deacetylase as a treatment for cardiac hypertrophy)

RN 9076-57-7 CAPLUS
CN Deacetylase, histone (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L42 ANSWER 32 OF 56 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2003:72949 CAPLUS <<LOGINID::20080505>>
DOCUMENT NUMBER: 139:190760
TITLE: Histone deacetylase inhibitors potently repress CXCR4 chemokine receptor expression and function in acute lymphoblastic leukemia
AUTHOR(S): Crazzolara, Roman; Johrer, Karin; Johnstone, Ricky W.; Greil, Richard; Kofler, Reinhard; Meister, Bernhard; Bernhard, David
CORPORATE SOURCE: Tyrolean Cancer Research Institute, Tyrolean Cancer Research Institute, University of Innsbruck, Innsbruck, Austria
SOURCE: British Journal of Haematology (2002), 119(4), 965-969
CODEN: BJHEAL; ISSN: 0007-1048
PUBLISHER: Blackwell Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The chemokine receptor CXCR4 plays a crucial role in the survival and trafficking of leukemia cells and requires further attention as human immunodeficiency virus type I (HIV-I) utilizes CXCR4 as the major coreceptor for cellular entry. We demonstrated that inhibitors of histone deacetylases, currently being tested in clin. trials for the treatment of various tumors, extensively downregulated CXCR4 protein and mRNA levels in leukemia cell lines and lymphoblasts from patients with childhood acute leukemia. As a result, the ability of stromal cell-derived factor-1 to induce cellular migration was impaired. Repression of CXCR4 transcription by inhibitors of histone deacetylases might therefore represent a promising novel approach in the treatment of acute leukemias.
IT 149647-78-9, Suberoylanilide hydroxamic acid
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(histone deacetylase inhibitors repression of CXCR4 chemokine receptor in ALL)
RN 149647-78-9 CAPLUS
CN Octanediamide, N1-hydroxy-N8-phenyl- (CA INDEX NAME)



IT 9076-57-7, Histone deacetylase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitor; histone deacetylase inhibitors repression of CXCR4 chemokine receptor in ALL)
RN 9076-57-7 CAPLUS
CN Deacetylase, histone (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L42 ANSWER 33 OF 56 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2003:52271 CAPLUS <<LOGINID::20080505>>
DOCUMENT NUMBER: 139:172905
TITLE: Histone acetylation and retinoic acid receptor β DNA methylation as novel targets for gastric cancer therapy
AUTHOR(S): Tahara, Eiichi
CORPORATE SOURCE: Hiroshima Cancer Seminar Foundation, Radiation Effects Research Foundation, Hiroshima University, Minami-ku, Horoshima, 732-0815, Japan
SOURCE: Drug News & Perspectives (2002), 15(9), 581-585
CODEN: DNPEED; ISSN: 0214-0934
PUBLISHER: Prous Science
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English

AB A review. Multiple genetic and epigenetic alterations in oncogenes, tumor-suppressor genes, cell-cycle regulators, cell adhesion mols. and DNA repair genes, as well as genetic instability and telomerase activation, are responsible for tumor genesis and progression of gastric cancer. The scenario of these epigenetic alterations found in gastric cancer differs, depending on the two types of gastric cancer, indicating that there are at least two types of CpG (cytidine phosphate guanosine) island methylator phenotypes in the intestinal-type and diffuse-type of gastric cancer. In addition to promoter methylation, acetylated histone H4 is obviously reduced in a majority of gastric carcinomas. Histone H4 is progressively deacetylated from the early stage (precancerous lesions) to the late stage (invasion and metastasis) in gastric carcinogenesis. Since there is no difference in the level of acetylated histone H4 between the intestinal-type and diffuse-type of gastric cancer, histone H4 deacetylation may be involved in both types of gastric cancer. This review proposes histone acetylation and retinoic acid receptor β DNA methylation as novel targets for gastric cancer therapy.

IT 149647-78-9, Suberoylanilide hydroxamic acid
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(histone acetylation and retinoic acid receptor β (RARβ) DNA methylation as novel targets for gastric cancer therapy)
RN 149647-78-9 CAPLUS
CN Octanediamide, N1-hydroxy-N8-phenyl- (CA INDEX NAME)

IT 9076-57-7, Histone deacetylase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibition; histone acetylation and retinoic acid receptor β (RARβ) DNA methylation as novel targets for gastric cancer therapy)
RN 9076-57-7 CAPLUS

CN Deacetylase, histone (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
REFERENCE COUNT: 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L42 ANSWER 34 OF 56 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:869074 CAPLUS <<LOGINID::20080505>>
DOCUMENT NUMBER: 137:363085
TITLE: Treatment of neurodegenerative, psychiatric, and other nervous system disorders associated with polyglutamine expansion using histone deacetylase inhibitors
INVENTOR(S): Steffan, Joan S.; Thompson, Leslie M.; Marsh, J. Lawrence; Bodai, Laszlo; Pallos, Judit
PATENT ASSIGNEE(S): The Regents of the University of California, USA
SOURCE: PCT Int. Appl., 69 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002090534	A1	20021114	WO 2002-US14167	20020502 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002340745	A1	20021118	AU 2002-340745	20020502 <--
EP 1390491	A1	20040225	EP 2002-769340	20020502 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 20040142859	A1	20040722	US 2003-476627	20031030 <--
US 20050227915	A1	20051013	US 2004-768292	20040129 <--
PRIORITY APPLN. INFO.:			US 2001-288215P	P 20010502 <--
			US 2002-372724P	P 20020411 <--
			WO 2002-US14167	W 20020502 <--
			US 2003-443717P	P 20030129
			US 2003-476627	A2 20031030

AB The invention relates to a novel method for treating a variety of diseases and disorders, including polyglutamine expansion diseases such as Huntington's disease, neurol. degeneration, psychiatric disorders, and protein aggregation disorders and diseases, comprising administering to patients in need thereof of a therapeutically effective amount of one or more deacetylase inhibitors. Specifically, histone deacetylases are targeted to limit the consequences of aberrant interaction between polyglutamine expansion variants of proteins and transcription factors, such as p53, to prevent aberrant gene expression. The invention is also directed to a transgenic fly useful as a model of polyglutamine expansion diseases, which may be used to test potential therapeutic agents.

IT 149647-78-9, SAHA 382180-17-8, Pyroxamide
RL: ANT (Analyte); BSU (Biological study, unclassified); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(for treating neurodegenerative disease; treatment of neurodegenerative, psychiatric, and other nervous system disorders associated with polyglutamine expansion using histone deacetylase inhibitors)
RN 149647-78-9 CAPLUS
CN Octanediamide, N1-hydroxy-N8-phenyl- (CA INDEX NAME)



RN 382180-17-8 CAPLUS
CN Octanediamide, N1-hydroxy-N8-3-pyridinyl- (CA INDEX NAME)



IT 9076-57-7, Histone deacetylase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitor; treatment of neurodegenerative, psychiatric, and other nervous system disorders associated with polyglutamine expansion using histone deacetylase inhibitors)
RN 9076-57-7 CAPLUS
CN Deacetylase, histone (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L42 ANSWER 35 OF 56 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:832643 CAPLUS <<LOGINID::20080505>>
DOCUMENT NUMBER: 137:304765
TITLE: Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
INVENTOR(S): Dimartino, Jorge
PATENT ASSIGNEE(S): Supergen, Inc., USA
SOURCE: PCT Int. Appl., 54 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
WO 2002085400	A1	20021031	WO 2002-US12092	20020419	<--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
US 20040204339	A1	20041014	US 2001-841744	20010424	<--
US 6905669	B2	20050614			
CA 2443560	A1	20021031	CA 2002-2443560	20020419	<--
AU 2002303376	A1	20021105	AU 2002-303376	20020419	<--
EP 1389127	A1	20040218	EP 2002-731396	20020419	<--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
US 20050159347	A1	20050721	US 2005-82130	20050315	<--
US 7276228	B2	20071002			

PRIORITY APPLN. INFO.: US 2001-841744 A1 20010424 <--
WO 2002-US12092 W 20020419 <--

AB Compns. and methods are provided for treating diseases associated with aberrant silencing of gene expression such as cancer by reestablishing the gene expression through inhibition of DNA hypomethylation and histone deacetylase. The method comprises: administering to a patient suffering from the disease a therapeutically effective amount of a DNA methylation inhibitor such as a cysteine analog such as decitabine, in combination with an effective amount of histone deacetylase inhibitor such as hydroxamic acid, cyclic peptide, benzamide, butyrate, and depudecin.

IT 9076-57-7, Histone deacetylase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(compns. and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase for treatment of diseases such as cancer)

RN 9076-57-7 CAPLUS

CN Deacetylase, histone (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 149647-78-9, SAHA 382180-17-8, Pyroxamide
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase for treatment of diseases such as cancer)

RN 149647-78-9 CAPLUS

CN Octanediamide, N1-hydroxy-N8-phenyl- (CA INDEX NAME)



RN 382180-17-8 CAPLUS
CN Octanediamide, N1-hydroxy-N8-3-pyridinyl- (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L42 ANSWER 36 OF 56 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:651684 CAPLUS <<LOGINID::20080505>>
DOCUMENT NUMBER: 138:198269
TITLE: Suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor, suppresses the growth of carcinogen-induced mammary tumors
AUTHOR(S): Cohen, Leonard A.; Marks, Paul A.; Rifkind, Richard A.; Amin, Shantu; Desai, Dhimant; Pittman, Brian; Richon, Victoria M.
CORPORATE SOURCE: American Health Foundation, Valhalla, NY, 10595, USA
SOURCE: Anticancer Research (2002), 22(3), 1497-1504
CODEN: ANTRD4; ISSN: 0250-7005
PUBLISHER: International Institute of Anticancer Research
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor, was shown to inhibit the development of N-methylnitrosourea (NMU)-induced rat mammary tumors when fed in the diet continuously for the duration of the carcinogenic process. The present study was designed to determine whether the inhibitory effects of SAHA occur during the initiation process or at subsequent stages in the carcinogenic process. In addition, animals with established NMU tumors were administered SAHA to determine whether SAHA could inhibit the continued growth of established mammary tumors. It was found that SAHA fed at 900 ppm in the diet inhibited tumor yields when administered from 14 days prior to NMU administration to termination (-14 to +130) and from +14 and +28 days to termination. However, SAHA had no effect on tumor yields when administered from -14 to +14 or from -14 to +50 days and then returned to the control diets for the remainder of the exptl. period (130 days). These results indicate that the inhibitory effects of SAHA are not exerted at the initiation phase of NMU-induced mammary tumorigenesis and appear, instead, to inhibit the subsequent stages in tumor development. Of most interest was the ability of SAHA to inhibit the growth of established mammary tumors. Administration, of SAHA in the diet at 900 ppm resulted in significant inhibition of established tumor growth. Thirty-two percent of SAHA-treated tumors exhibited partial regression compared to 12% of controls, growth was stabilized in 24% of treated tumors compared to 12% of controls while 11% exhibited complete regression compared to 0% of controls. Collectively, SAHA-treated tumors exhibited a 7 fold reduction in growth compared to untreated tumors over the

test period. The results of this animal model study indicate that SAHA, when fed in the diet, serves as both a chemopreventive and chemotherapeutic agent in the absence of any detectable side effects.
IT 9076-57-7, Histone deacetylase
RL: BSU (Biological study, unclassified); BIOL (Biological study) (inhibitor; suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, suppresses growth of mammary tumors)
RN 9076-57-7 CAPLUS
CN Deacetylase, histone (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
IT 149647-78-9, SAHA
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, suppresses growth of mammary tumors)
RN 149647-78-9 CAPLUS
CN Octanediamide, N1-hydroxy-N8-phenyl- (CA INDEX NAME)



REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L42 ANSWER 37 OF 56 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:594666 CAPLUS <<LOGINID::20080505>>
DOCUMENT NUMBER: 137:135074
TITLE: Use of retinoids plus histone deacetylase inhibitors to inhibit the growth of solid tumors
INVENTOR(S): Gudas, Lorraine J.; Nanus, David
PATENT ASSIGNEE(S): Cornell Research Foundation, Inc., USA
SOURCE: PCT Int. Appl., 40 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002060430	A1	20020808	WO 2002-US2976	20020201 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002242057	A1	20020812	AU 2002-242057	20020201 <--

US 20020183388 A1 20021205 US 2002-61101 20020201 <--
PRIORITY APPLN. INFO.: US 2001-265651P P 20010201 <--
WO 2002-US2976 W 20020201 <--

AB The invention provides a method of inhibiting growth of solid tumors in an animal which comprises administering an effective amount of trichostatin A to an animal in need of such treatment. The invention also provides a method of inhibiting growth of solid tumors in an animal which comprises administering an effective amount of a histone deacetylase inhibitor and a retinoid to an animal in need of such treatment. Examples of solid tumors which may be treated using the methods of the invention include but are not limited to carcinomas of the head and neck, breast, skin, kidney, oral cavity, colon, prostate, pancreas and lung.

IT 9076-57-7, Histone deacetylase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(retinoids and histone deacetylase inhibitors for inhibition of growth of solid tumors)
RN 9076-57-7 CAPLUS
CN Deacetylase, histone (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 149647-78-9
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(retinoids and histone deacetylase inhibitors for inhibition of growth of solid tumors)
RN 149647-78-9 CAPLUS
CN Octanediamide, N1-hydroxy-N8-phenyl- (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L42 ANSWER 38 OF 56 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:539823 CAPLUS <<LOGINID::20080505>>
DOCUMENT NUMBER: 137:103874
TITLE: Histone deacetylase inhibitors enhancing iodide or iodine uptake and uses in diagnosis and treatment of thyroid neoplasms
INVENTOR(S): Fojo, Antonio Tito; Bates, Susan Elaine
PATENT ASSIGNEE(S): The Government of the United States of America, Department of Health & Human Services, USA
SOURCE: PCT Int. Appl., 55 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

```
     WO 2002055688         A2    20020718    WO 2002-US714          20020108 <--
     WO 2002055688         A3    20030410
     WO 2002055688         A8    20030925
          W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
              CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
              GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
              LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
              PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
              UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
          RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
              KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB,
              GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA,
              GN, GQ, GW, ML, MR, NE, SN, TD, TG
     AU 2002249938         A1    20020724    AU 2002-249938         20020108 <--
     CA 2434269            A1    20020718    CA 2002-2434269        20020109 <--
     EP 1356053            A2    20031029    EP 2002-718823         20020109 <--
          R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
              IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
     JP 2005507231         T     20050317    JP 2002-556736         20020109 <--
     US 20040132643        A1    20040708    US 2004-250320         20040102 <--
PRIORITY APPLN. INFO.:                       US 2001-260733P     P  20010110 <--
                                             WO 2002-US714       W  20020108 <--
```

AB Disclosed herein are novel approaches to thyroid cancer therapy. These approaches include methods to enhance thyroid specific gene expression, for example methods to enhance expression of thyroglobulin and/or the Na+/I- symporter in thyroid cancer cells. Enhanced expression of thyroid-specific genes promotes cellular differentiation and reduces biol. aggressive behavior such as invasion and metastasis. In addition, enhanced expression of thyroglobulin and/or the Na+/I- symporter increases the ability of thyroid cancer cells to concentrate iodine or iodide, thereby making the cells more susceptible to radioactive iodine therapy. Also disclosed herein are methods for detecting thyroid neoplasms in a subject, by administering a therapeutically effective amount of a histone deacetylase inhibitor, administering a detectable agent whose uptake or concentration in thyroid cells is increased by administration of the histone deacetylase inhibitor, and detecting the detectable agent.

```
IT   9076-57-7, Histone deacetylase
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (histone deacetylase inhibitors enhancing iodide or iodine uptake and
        uses in diagnosis and treatment of thyroid neoplasms)
RN   9076-57-7  CAPLUS
CN   Deacetylase, histone  (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
IT   149647-78-9
     RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
        (histone deacetylase inhibitors enhancing iodide or iodine uptake and
        uses in diagnosis and treatment of thyroid neoplasms)
RN   149647-78-9  CAPLUS
CN   Octanediamide, N1-hydroxy-N8-phenyl-  (CA INDEX NAME)
```



L42 ANSWER 39 OF 56 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:539476 CAPLUS <<LOGINID::20080505>>
DOCUMENT NUMBER: 137:88450
TITLE: Method of treating autoimmune diseases with histone hyperacetylating agent
INVENTOR(S): Kammer, Gary M.; Mishra, Nilamadhab
PATENT ASSIGNEE(S): Wake Forest University, USA
SOURCE: PCT Int. Appl., 31 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
WO 2002055017	A2	20020718	WO 2001-US43871	20011119	<--
WO 2002055017	A3	20030123			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
AU 2002243231	A1	20020724	AU 2002-243231	20011119	<--
US 20030114525	A1	20030619	US 2002-151481	20020520	<--
US 7271198	B2	20070918			
US 20030082666	A1	20030501	US 2002-187586	20020702	<--
US 20060178437	A1	20060810	US 2006-403608	20060413	<--

PRIORITY APPLN. INFO.:
US 2000-718195 A 20001120 <--
WO 2001-US43871 W 20011119 <--
US 2002-187586 A3 20020702 <--

AB A method of treating an autoimmune disease (for example, Systemic Lupus Erythematosus) comprises administering to the subject a treatment effective amount of a histone hyperacetylating agent, or a pharmaceutically acceptable salt thereof. Methods of screening compds. useful for the treatment of autoimmune disease are also disclosed. Trichostatin A down-regulated CD154 and interleukin 10 and up-regulated interferon-γ in SLE T cells.

IT 9076-57-7, Histone deacetylase
RL: ARG (Analytical reagent use); BSU (Biological study, unclassified); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(inhibitor; method of treating autoimmune diseases with histone hyperacetylating agent)

RN 9076-57-7 CAPLUS
CN Deacetylase, histone (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 149647-78-9
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(method of treating autoimmune diseases with histone hyperacetylating agent)
RN 149647-78-9 CAPLUS
CN Octanediamide, N1-hydroxy-N8-phenyl- (CA INDEX NAME)



L42 ANSWER 40 OF 56 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:496846 CAPLUS <<LOGINID::20080505>>
DOCUMENT NUMBER: 138:198218
TITLE: Synergistic induction of mitochondrial damage and apoptosis in human leukemia cells by flavopiridol and the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA)
AUTHOR(S): Almenara, J.; Rosato, R.; Grant, S.
CORPORATE SOURCE: Medical College of Virginia, Department of Medicine, Virginia Commonwealth University, Richmond, VA, USA
SOURCE: Leukemia (2002), 16(7), 1331-1343
CODEN: LEUKED; ISSN: 0887-6924
PUBLISHER: Nature Publishing Group
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Interactions between the histone deacetylase inhibitor SAHA (suberoylanilide hydroxamic acid) and the cyclin-dependent kinase (CDK) inhibitor flavopiridol (FP) were examined in human leukemia cells. Simultaneous exposure (24 h) of myelomonocytic leukemia cells (U937) to SAHA (1 μM) and FP (100 nM), which were minimally toxic alone (1.5 and 16.3% apoptosis resp.), produced a dramatic increase in cell death (ie 63.2% apoptotic), reflected by morphol., procaspase-3 and -8 cleavage, Bid activation, diminished ΔΨm, and enhanced cytochrome c release. FP blocked SAHA-mediated up-regulation of p21CIP1 and CD11b expression, while inducing caspase-dependent Bcl-2 and pRb cleavage. Similar interactions were observed in HL-60 and Jurkat leukemic cells. Enhanced apoptosis in SAHA/FP-treated cells was accompanied by a marked reduction in clonogenic survival. Ectopic expression of either dominant-neg. caspase-8 (C8-DN) or CrmA partially attenuated SAHA/FP-mediated apoptosis (eg 45 and 38.2% apoptotic vs 78% in controls) and Bid cleavage. SAHA/FP induced-apoptosis was unaffected by the free radical scavenger L-N-acetyl Cys or the PKC inhibitor GFX. Finally, ectopic Bcl-2 expression marginally attenuated SAHA/FP-related apoptosis/cytochrome c release, and failed to restore clonogenicity in cells exposed to these agents. Together, these findings indicate that SAHA and FP interact synergistically to induce mitochondrial damage and apoptosis in human leukemia cells, and suggest that this process may also involve engagement of the caspase-8-dependent apoptotic cascade.
IT 9076-57-7, Histone deacetylase
RL: BSU (Biological study, unclassified); BIOL (Biological study) (inhibitor; synergistic interaction of flavopiridol and SAHA in leukemia)
RN 9076-57-7 CAPLUS

CN Deacetylase, histone (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
IT 149647-78-9, SAHA
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(synergistic interaction of flavopiridol and SAHA in leukemia)
RN 149647-78-9 CAPLUS
CN Octanediamide, N1-hydroxy-N8-phenyl- (CA INDEX NAME)



REFERENCE COUNT: 50 THERE ARE 50 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L42 ANSWER 41 OF 56 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:462894 CAPLUS <<LOGINID::20080505>>
DOCUMENT NUMBER: 137:179388
TITLE: Structure-Activity Relationships on Phenylalanine-Containing Inhibitors of Histone Deacetylase: In Vitro Enzyme Inhibition, Induction of Differentiation, and Inhibition of Proliferation in Friend Leukemic Cells
AUTHOR(S): Wittich, Sybille; Scherf, Hans; Xie, Changping; Brosch, Gerald; Loidl, Peter; Gerhaeuser, Clarissa; Jung, Manfred
CORPORATE SOURCE: Department of Pharmaceutical and Medicinal Chemistry, Westfaelische Wilhelms-Universitaet Muenster, Muenster, 48149, Germany
SOURCE: Journal of Medicinal Chemistry (2002), 45(15), 3296-3309
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 137:179388

AB Inhibitors of histone deacetylases (HDACs) are a new class of anticancer agents that affect gene regulation. We had previously reported the first simple synthetic HDAC inhibitors with in vitro activity at submicromolar concns. Here, we present structure-activity data on modifications of a phenylalanine-containing lead compound including amino acid amides as well as variations of the amino acid part. The compds. were tested for inhibition of maize HD-2, rat liver HDAC, and for the induction of terminal cell differentiation and inhibition of proliferation in Friend leukemic cells. In the amide series, in vitro inhibition was potentiated up to 15-fold, but the potential to induce cell differentiation decreased. Interestingly, an HDAC class selectivity was indicated among some of these amides. In the amino acid Me ester series, a biphenylalanine derivative was identified as a good enzyme inhibitor, which blocks proliferation in the submicromolar range and is also a potent inducer of terminal cell differentiation.

IT 9076-57-7, Histone deacetylase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(preparation and structure-activity relationships on phenylalanine-containing
inhibitors of histone deacetylase in Friend leukemic cells)
RN 9076-57-7 CAPLUS
CN Deacetylase, histone (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
IT 149647-78-9, SAHA
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation and structure-activity relationships on phenylalanine-containing
inhibitors of histone deacetylase in Friend leukemic cells)
RN 149647-78-9 CAPLUS
CN Octanediamide, N1-hydroxy-N8-phenyl- (CA INDEX NAME)

REFERENCE COUNT: 52 THERE ARE 52 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L42 ANSWER 42 OF 56 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:298819 CAPLUS <<LOGINID::20080505>>
DOCUMENT NUMBER: 137:210564
TITLE: Suberoylanilide hydroxamic acid (SAHA) overcomes multidrug resistance and induces cell death in P-glycoprotein-expressing cells
AUTHOR(S): Ruefli, Astrid A.; Bernhard, David; Tainton, Kellie M.; Kofler, Reinhard; Smyth, Mark J.; Johnstone, Ricky W.
CORPORATE SOURCE: Cancer Immunology Division, The Peter MacCallum Cancer Institute, East Melbourne, 3002, Australia
SOURCE: International Journal of Cancer (2002), 99(2), 292-298
CODEN: IJCNAW; ISSN: 0020-7136
PUBLISHER: Wiley-Liss, Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Multidrug resistance (MDR) mediated by the ATP-dependent efflux protein P-glycoprotein (P-gp) is a major obstacle to the successful treatment of many cancers. In addition to effluxing toxins, P-gp has been shown to protect tumor cells against caspase-dependent apoptosis mediated by Fas and tumor necrosis factor receptor (TNFR) ligation, serum starvation and UV irradiation However, P-gp does not protect against caspase-independent cell death mediated by granzyme B or pore-forming proteins (perforin, pneumolysin and activated complement). The authors examined the effects of the chemotherapeutic hybrid polar compound suberoylanilide hydroxamic acid (SAHA) on P-gp-expressing MDR human tumor cell lines. In the CEM T-cell line, SAHA, a histone deacetylase inhibitor, induced equivalent death in

P-gp-pos. cells compared with P-gp-neg. cells. Cell death was marked by the caspase-independent release of cytochrome c, reactive oxygen species (ROS) production and Bid cleavage that was not affected by P-gp expression. However, consistent with the authors' previous findings, SAHA-induced caspase activation was inhibited in P-gp-expressing cells. These data provide evidence that P-gp inhibits caspase activation after chemotherapeutic drug treatment and demonstrates that SAHA may be of value for the treatment of P-gp-expressing MDR cancers.

IT 9076-57-7, Histone deacetylase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; suberoylanilide hydroxamic acid overcomes P-glycoprotein-mediated multidrug resistance and induces cell death human tumor cells and mechanism involved)
RN 9076-57-7 CAPLUS
CN Deacetylase, histone (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
IT 149647-78-9, SAHA
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(suberoylanilide hydroxamic acid overcomes P-glycoprotein-mediated multidrug resistance and induces cell death human tumor cells and mechanism involved)
RN 149647-78-9 CAPLUS
CN Octanediamide, N1-hydroxy-N8-phenyl- (CA INDEX NAME)



REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L42 ANSWER 43 OF 56 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:256222 CAPLUS <<LOGINID::20080505>>
DOCUMENT NUMBER: 136:294651
TITLE: Preparation of aryl-substituted N-hydroxy amides with amide linkages as HDAC inhibitors for treatment of proliferative conditions
INVENTOR(S): Watkins, Clare J.; Romero-Martin, Maria-Rosario; Moore, Kathryn G.; Ritchie, James; Finn, Paul W.; Kalvinsh, Ivars; Loza, Einars; Starchenkov, Igor; Dikovska, Klara; Bokaldere, Rasma Melita; Gailite, Vija; Vorona, Maxim; Andrianov, Victor; Lolya, Daina; Semenikhina, Valentina; Amolins, Andris; Harris, C. John; Duffy, James E. S.
PATENT ASSIGNEE(S): Prolifix Limited, UK
SOURCE: PCT Int. Appl., 346 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002026696	A1	20020404	WO 2001-GB4329	20010927 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2423868	A1	20020404	CA 2001-2423868	20010927 <--
AU 2001090134	A	20020408	AU 2001-90134	20010927 <--
EP 1335898	A1	20030820	EP 2001-970014	20010927 <--
EP 1335898	B1	20051123		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004509941	T	20040402	JP 2002-531082	20010927 <--
EP 1598067	A1	20051123	EP 2005-15737	20010927 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
AT 310719	T	20051215	AT 2001-970014	20010927 <--
ES 2257441	T3	20060801	ES 2001-970014	20010927 <--
US 20040092598	A1	20040513	US 2003-381791	20030827 <--
PRIORITY APPLN. INFO.:			GB 2000-23985 A	20000929 <--
			US 2001-297785P P	20010614 <--
			EP 2001-970014 A3	20010927 <--
			WO 2001-GB4329 W	20010927 <--

OTHER SOURCE(S): MARPAT 136:294651

AB The title compds. AQ1JQ2CONHOH [I; wherein A = aryl group; Q1 = aryl leader group having a backbone of at least 2 C atoms; J = NR1CO or CONR1; R1 = amido substituent; Q2 = acid leader group; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemical protected forms, and prodrugs thereof] were prepared via solution phase and solid phase synthetic methods as histone deacetylase (HDAC) inhibitors for treatment of proliferative conditions, such as cancer and psoriasis. For example, 6-aminocaproic acid Me ester•HCl was coupled with 2-naphthoyl chloride in the presence of diisopropyl ethylamine in DMF to give the amide. Deesterification (79%), followed by conversion to the N-hydroxyamide using HONH2•HCl in the presence of 1,1'-carbonyldiimidazole in THF, afforded naphthalene-2-carboxylic acid (5-hydroxycarbamoylpentyl)amide II (PX105687) in 40% yield. The latter inhibited recombinant HDAC1 and HDAC2 with IC50 values of 33 nM and 29 nM, resp., and inhibited cell proliferation against the human cervical adenocarcinoma (HeLa) cell line using cell proliferation reagent WST-1 with IC50 of 1.1 nM. Structure-activity relationship studies showed superior activity for I when (1) the backbone of Q1 had > 1 carbon atoms, and (2) the alkylene group Q2 had > 5 carbon atoms.

IT 408357-61-9P, PX 116218 408357-69-7P, PX 116223
408357-72-2P, PX 117720
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(HDAC inhibitor; preparation of N-hydroxy amides with amide linkages as HDAC

inhibitors for treatment of proliferative conditions)
RN 408357-61-9 CAPLUS
CN Octanediamide, N-hydroxy-N'-1-naphthalenyl- (9CI) (CA INDEX NAME)



RN 408357-69-7 CAPLUS
CN Octanediamide, N-hydroxy-N'-2-naphthalenyl- (9CI) (CA INDEX NAME)



RN 408357-72-2 CAPLUS
CN Octanediamide, N-[1,1'-biphenyl]-4-yl-N'-hydroxy- (9CI) (CA INDEX NAME)



IT 9076-57-7, Histone deacetylase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(preparation of N-hydroxy amides with amide linkages as HDAC inhibitors for treatment of proliferative conditions)
RN 9076-57-7 CAPLUS
CN Deacetylase, histone (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L42 ANSWER 44 OF 56 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:224891 CAPLUS <<LOGINID::20080505>>
DOCUMENT NUMBER: 137:72839
TITLE: The antitumor histone deacetylase inhibitor

suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines

AUTHOR(S): Leoni, Flavio; Zaliani, Andrea; Bertolini, Giorgio; Porro, Giulia; Pagani, Paolo; Pozzi, Pietro; Dona, Giancarlo; Fossati, Gianluca; Sozzani, Silvano; Azam, Tania; Bufler, Philip; Fantuzzi, Giamila; Goncharov, Igor; Kim, Soo-Hyun; Pomerantz, Benjamin J.; Reznikov, Leonid L.; Siegmund, Britta; Dinarello, Charles A.; Mascagni, Paolo

CORPORATE SOURCE: Italfarmaco, SpA., Balsamo, 20092, Italy

SOURCE: Proceedings of the National Academy of Sciences of the United States of America (2002), 99(5), 2995-3000
CODEN: PNASA6; ISSN: 0027-8424

PUBLISHER: National Academy of Sciences

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Suberoylanilide hydroxamic acid (SAHA) is a hydroxamic acid-containing hybrid polar mol.; SAHA specifically binds to and inhibits the activity of histone deacetylase. Although SAHA, like other inhibitors of histone deacetylase, exhibits antitumor effects by increasing expression of genes regulating tumor survival, we found that SAHA reduces the production of proinflammatory cytokines in vivo and in vitro. A single oral administration of SAHA to mice dose-dependently reduced circulating TNF-α, IL-1β, IL-6, and IFN-γ induced by lipopolysaccharide (LPS). Administration of SAHA also reduced hepatic cellular injury in mice following i.v. injection of Con A. SAHA inhibited nitric oxide release in mouse macrophages stimulated by the combination of TNF-α plus IFN-γ. Human peripheral blood mononuclear cells stimulated with LPS in the presence of SAHA released less TNF-α, IL-1β, IL-12, and IFN-γ (50% reduction at 100-200 nM). The production of IFN-γ stimulated by IL-18 plus IL-12 was also inhibited by SAHA (85% at 200 nM). However, SAHA did not affect LPS-induced synthesis of the IL-1β precursor, the IL-1 receptor antagonist, or the chemokine IL-8. In addition, IFN-γ induced by anti-CD3 was not suppressed by SAHA. Steady-state mRNA levels for LPS-induced TNF-α and IFN-γ in peripheral blood mononuclear cells were markedly decreased, whereas IL-8 and IL-1β mRNA levels were unaffected. Because SAHA exhibits antiinflammatory properties in vivo and in vitro, inhibitors of histone deacetylase may stimulate the expression of genes that control the synthesis of cytokines and nitric oxide or hyper-acetylate other targets.

IT 9076-57-7, Histone deacetylase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines)
RN 9076-57-7 CAPLUS
CN Deacetylase, histone (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
IT 149647-78-9
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines)
RN 149647-78-9 CAPLUS

CN Octanediamide, N1-hydroxy-N8-phenyl- (CA INDEX NAME)



REFERENCE COUNT: 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L42 ANSWER 45 OF 56 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:220378 CAPLUS <<LOGINID::20080505>>
DOCUMENT NUMBER: 136:241653
TITLE: Promotion of apoptosis in cancer cells by co-administration of cyclin dependent kinase inhibitors and cellular differentiation agents
INVENTOR(S): Grant, Steven; Dent, Paul; Rosato, Roberto; Cartee, Leanne
PATENT ASSIGNEE(S): Virginia Commonwealth University, USA
SOURCE: PCT Int. Appl., 62 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002022133	A1	20020321	WO 2001-US28297	20010907 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2001087157	A5	20020326	AU 2001-87157	20010907 <--
US 20050004007	A1	20050106	US 2003-363540	20030305 <--
PRIORITY APPLN. INFO.:			US 2000-231885P P	20000912 <--
			WO 2001-US28297 W	20010907 <--

AB The invention provides compns. and methods for promoting apoptosis of cancer cells, and methods for treating cancer. The compns. comprise cyclin dependent kinase inhibitor and an agent that induces cellular differentiation. The methods of promoting apoptosis of cancer cells involve the co-administration to the cancer cells of a cyclin dependent kinase inhibitor and an agent that induces cell differentiation. The method for treating cancer involves the co-administration of a cyclin dependent kinase inhibitor and an agent that induces cellular differentiation to a patient. Examples of cellular differentiation agents include histone deacetylase inhibitors, protein kinase C activators, retinoids, and Vitamin D3.

IT 149647-78-9

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(histone deacetylase inhibitor; promotion of apoptosis in cancer cells by co-administration of cyclin dependent kinase inhibitors and cellular differentiation agents)
RN 149647-78-9 CAPLUS
CN Octanediamide, N1-hydroxy-N8-phenyl- (CA INDEX NAME)

IT 9076-57-7, Histone deacetylase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; promotion of apoptosis in cancer cells by co-administration of cyclin dependent kinase inhibitors and cellular differentiation agents)
RN 9076-57-7 CAPLUS
CN Deacetylase, histone (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L42 ANSWER 46 OF 56 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:108360 CAPLUS <<LOGINID::20080505>>
DOCUMENT NUMBER: 136:395648
TITLE: Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling
AUTHOR(S): Deroanne, Christophe F.; Bonjean, Karine; Servotte, Sandrine; Devy, Laetitia; Colige, Alain; Clausse, Nathalie; Blacher, Sylvia; Verdin, Eric; Foidart, Jean-Michel; Nusgens, Betty V.; Castronovo, Vincent
CORPORATE SOURCE: Research Center in Experimental Cancerology, Laboratory of Connective Tissues Biology, University of Liege, Liege, B-4000, Belg.
SOURCE: Oncogene (2002), 21(3), 427-436
CODEN: ONCNES; ISSN: 0950-9232
PUBLISHER: Nature Publishing Group
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Angiogenesis is a complex biol. process involving the coordinated modulation of many genes. Histone deacetylases (HDAC) are a growing family of enzymes that mediate the availability of chromatin to the transcriptional machinery. Trichostatin-A (TSA) and suberoylanilide hydroxamic acid (SAHA), two HDAC inhibitors known to relieve gene silencing, were evaluated as potential antiangiogenic agents. TSA and SAHA were shown to prevent vascular endothelial growth factor (VEGF)-stimulated human umbilical cord endothelial cells (HUVEC) from invading a type I collagen gel and forming capillary-like structures. SAHA and TSA inhibited the VEGF-induced formation of a CD31-pos. capillary-like network in embryoid bodies and inhibited the VEGF-induced

angiogenesis in the CAM assay. TSA also prevented, in a dose-response relation, the sprouting of capillaries from rat aortic rings. TSA inhibited in a dose-dependent and reversible fashion the VEGF-induced expression of VEGF receptors, VEGFR1, VEGFR2, and neuropilin-1. TSA and SAHA upregulated the expression by HUVEC of semaphorin III, a recently described VEGF competitor, at both mRNA and protein levels. This effect was specific to endothelial cells and was not observed in human fibroblasts neither in vascular smooth muscle cells. These observations provide a conspicuous demonstration that HDAC inhibitors are potent anti-angiogenic factors altering VEGF signaling.

IT 9076-57-7, Histone deacetylase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling)
RN 9076-57-7 CAPLUS
CN Deacetylase, histone (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 149647-78-9
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling)
RN 149647-78-9 CAPLUS
CN Octanediamide, N1-hydroxy-N8-phenyl- (CA INDEX NAME)



REFERENCE COUNT: 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L42 ANSWER 47 OF 56 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:9423 CAPLUS <<LOGINID::20080505>>
DOCUMENT NUMBER: 136:241518
TITLE: Histone deacetylase inhibitors reduce polyglutamine toxicity
AUTHOR(S): McCampbell, Alexander; Taye, Addis A.; Whitty, Leslie; Penney, Ellen; Steffan, Joan S.; Fischbeck, Kenneth H.
CORPORATE SOURCE: Neurogenetics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, 20892, USA
SOURCE: Proceedings of the National Academy of Sciences of the United States of America (2001), 98(26), 15179-15184
CODEN: PNASA6; ISSN: 0027-8424
PUBLISHER: National Academy of Sciences
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Polyglutamine diseases include at least nine neurodegenerative disorders, each caused by a CAG repeat expansion in a different gene. Accumulation of mutant polyglutamine-containing proteins occurs in patients, and evidence

from cell culture and animal expts. suggests the nucleus as a site of pathogenesis. To understand the consequences of nuclear accumulation, the authors created a cell culture system with nuclear-targeted polyglutamine. In the authors system, cell death can be mitigated by overexpression of full-length cAMP response element binding protein (CREB)-binding protein (CBP) or its amino-terminal portion alone. CBP is one of several histone acetyltransferases sequestered by polyglutamine inclusions. The authors found histone acetylation to be reduced in cells expressing mutant polyglutamine. Reversal of this hypoacetylation, which can be achieved either by overexpression of CBP or its amino terminus or by treatment with deacetylase inhibitors, reduced cell loss. These findings suggest that nuclear accumulation of polyglutamine can lead to altered protein acetylation in neurons and indicate a novel therapeutic strategy for polyglutamine disease.

IT 9076-57-7, Histone deacetylase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(histone deacetylase inhibitors reduce polyglutamine toxicity in neurons in relation to CBP transcription factor expression)
RN 9076-57-7 CAPLUS
CN Deacetylase, histone (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
IT 149647-78-9
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(histone deacetylase inhibitors reduce polyglutamine toxicity in neurons in relation to CBP transcription factor expression)
RN 149647-78-9 CAPLUS
CN Octanediamide, N1-hydroxy-N8-phenyl- (CA INDEX NAME)

REFERENCE COUNT: 53 THERE ARE 53 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L42 ANSWER 48 OF 56 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2001:914781 CAPLUS <<LOGINID::20080505>>
DOCUMENT NUMBER: 136:193822
TITLE: The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells
AUTHOR(S): Munster, Pamela N.; Troso-Sandoval, Tiffany; Rosen, Neal; Rifkind, Richard; Marks, Paul A.; Richon, Victoria M.
CORPORATE SOURCE: Program in Cell Biology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, 10021, USA
SOURCE: Cancer Research (2001), 61(23), 8492-8497
CODEN: CNREA8; ISSN: 0008-5472
PUBLISHER: American Association for Cancer Research
DOCUMENT TYPE: Journal

LANGUAGE: English

AB Histone deacetylase (HDACs) regulate histone acetylation by catalyzing the removal of acetyl groups on the NH2-terminal lysine residues of the core nucleosomal histones. Modulation of the acetylation status of core histones is involved in the regulation of the transcriptional activity of certain genes. HDAC activity is generally associated with transcriptional repression. Aberrant recruitment of HDAC activity has been associated with the development of certain human cancers. We have developed a class of HDAC inhibitors, such as suberoylanilide hydroxamic acid (SAHA), that were initially identified based on their ability to induce differentiation of cultured murine erythroleukemia cells. Addnl. studies have demonstrated that SAHA inhibits the growth of tumors in rodents. In this study we have examined the effects of SAHA on MCF-7 human breast cancer cells. We found that SAHA causes the inhibition of proliferation, accumulation of cells in a dose-dependent manner in G1 then G2-M phase of the cell cycle, and induction of milk fat globule protein, milk fat membrane globule protein, and lipid droplets. Growth inhibition was associated with morphol. changes including the flattening and enlargement of the cytoplasm, and a decrease in the nuclear: cytoplasmic ratio. Withdrawal of SAHA led to reentry of cells into the cell cycle and reversal to a less differentiated phenotype. SAHA induced differentiation in the estrogen receptor-neg. cell line SKBr-3 and the retinoblastoma-neg. cell line MDA-468. We propose that SAHA has profound antiproliferative activity by causing these cells to undergo cell cycle arrest and differentiation that is dependent on the presence of SAHA. SAHA and other HDAC inhibitors are currently in Phase I clin. trials. These findings may impact the clin. use of these drugs.

IT 9076-57-7, Histone deacetylase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells)

RN 9076-57-7 CAPLUS

CN Deacetylase, histone (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 149647-78-9, SAHA
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells)

RN 149647-78-9 CAPLUS

CN Octanediamide, N1-hydroxy-N8-phenyl- (CA INDEX NAME)



REFERENCE COUNT: 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L42 ANSWER 49 OF 56 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2001:908905 CAPLUS <<LOGINID::20080505>>

DOCUMENT NUMBER: 137:87961

TITLE: Histone deacetylase inhibitors induce

caspase-dependent apoptosis and downregulation of daxx in acute promyelocytic leukaemia with t(15;17)

AUTHOR(S): Amin, Hesham M.; Saeed, Shahnaz; Alkan, Serhan
CORPORATE SOURCE: Department of Pathology, Loyola University Medical Center, Maywood, IL, 60153, USA

SOURCE: British Journal of Haematology (2001), 115(2), 287-297
CODEN: BJHEAL; ISSN: 0007-1048
PUBLISHER: Blackwell Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Histone deacetylase (HDAC) appears to play an important role in the pathogenesis of acute promyelocytic leukemia (APL) as it is recruited by both PML-RARα and PLZF/RARα in leukemic cells with t(15;17) and t(11;17), resp. Recent studies have demonstrated that HDAC inhibitors can be therapeutically used in various neoplastic disorders including APL. Cell differentiation was considered the major mechanism of the anti-leukemic effects of HDAC inhibitors in APL. However, most of these studies either evaluated the effect of HDAC inhibitors in combination with all-trans retinoic acid (ATRA) or focused on the less common form of APL with t(11;17). To investigate the cellular effects of HDAC inhibitors, including sodium butyrate, trichostatin A, and suberoylanilide hydroxamic acid (SAHA), we used two APL cell lines, NB4 and the ATRA-resistant derivative NB4.306. Moreover, primary cells from five patients with cytogenetic evidence for t(15;17) were also studied. Our results demonstrated that HDAC inhibitors induce distinct caspase-dependent apoptosis in APL, which showed both concentration- and time-dependence. In addition, changes in the apoptosis-regulatory proteins, daxx, bcl-2 and bax were analyzed. HDAC inhibitors induced downregulation of daxx, but no significant changes were detected in bcl-2 or bax. In conclusion, apoptosis induced by HDAC inhibitors in APL could provide an effective strategy for treatment of patients with t(15;17).

IT 149647-78-9, SAHA
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(histone deacetylase inhibitors induce caspase-dependent apoptosis and downregulation of daxx in acute promyelocytic leukemia with t(15;17))
RN 149647-78-9 CAPLUS
CN Octanediamide, N1-hydroxy-N8-phenyl- (CA INDEX NAME)

IT 9076-57-7, Histone deacetylase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; histone deacetylase inhibitors induce caspase-dependent apoptosis and downregulation of daxx in acute promyelocytic leukemia with t(15;17))
RN 9076-57-7 CAPLUS
CN Deacetylase, histone (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

REFERENCE COUNT: 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L42 ANSWER 50 OF 56 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2001:867915 CAPLUS <<LOGINID::20080505>>
DOCUMENT NUMBER: 137:72300
TITLE: Histone deacetylase inhibitors as new cancer drugs
AUTHOR(S): Marks, Paul A.; Richon, Victoria M.; Breslow, Ronald; Rifkind, Richard A.
CORPORATE SOURCE: Cell Biology Program, Memorial Sloan-Kettering Cancer Center, New York, NY, 10021, USA
SOURCE: Current Opinion in Oncology (2001), 13(6), 477-483
CODEN: CUOOE8; ISSN: 1040-8746
PUBLISHER: Lippincott Williams & Wilkins
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English

AB A review. Histone deacetylase inhibitors are potent inducers of growth arrest, differentiation, or apoptotic cell death in a variety of transformed cells in culture and in tumor bearing animals. Histone deacetylases and the family of histone acetyl transferases are involved in determining the acetylation of histones, which play a role in regulation of gene expression. Radiograph crystallog. studies reveal that the histone deacetylase inhibitors, suberoylanilide hydroxamic acid and trichostatin A, fit into the catalytic site of histone deacetylase, which has a tubular structure with a zinc atom at its base. The hydroxamic acid moiety of the inhibitor binds to the zinc. Histone deacetylase inhibitors cause acetylated histones to accumulate in both tumor and peripheral circulating mononuclear cells. Accumulation of acetylated histones has been used as a marker of the biol. activity of the agents. Hydroxamic acid-based histone deacetylase inhibitors limit tumor cell growth in animals with little or no toxicity. These compds. act selectively on genes, altering the transcription of only approx. 2% of expressed genes in cultured tumor cells. A number of proteins other than histones are substrates for histone deacetylases. The role that these other targets play in histone deacetylase inducement of cell growth arrest, differentiation, or apoptotic cell death is not known. This review summarizes the characteristics of a variety of inhibitors of histone deacetylases and their effects on transformed cells in culture and tumor growth in animal models. Several structurally different histone deacetylase inhibitors are in phase I or II clin. trials in patients with cancers.

IT 149647-78-9
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(histone deacetylase inhibitors as new cancer drugs)

RN 149647-78-9 CAPLUS
CN Octanediamide, N1-hydroxy-N8-phenyl- (CA INDEX NAME)



IT 9076-57-7, Histone deacetylase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; histone deacetylase inhibitors as new cancer drugs)
RN 9076-57-7 CAPLUS
CN Deacetylase, histone (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
REFERENCE COUNT: 54 THERE ARE 54 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L42 ANSWER 51 OF 56 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2001:363640 CAPLUS <<LOGINID::20080505>>
DOCUMENT NUMBER: 136:48071
TITLE: Inhibition of transformed cell growth and induction of cellular differentiation by pyroxamide, an inhibitor of histone deacetylase
AUTHOR(S): Butler, Lisa M.; Webb, Yael; Agus, David B.; Higgins, Brian; Tolentino, Thomas R.; Kutko, Martha C.; LaQuaglia, Michael P.; Drobnjak, Marija; Cordon-Cardo, Carlos; Scher, Howard I.; Breslow, Ronald; Richon, Victoria M.; Rifkind, Richard A.; Marks, Paul A.
CORPORATE SOURCE: Cell Biology Program, Memorial Sloan-Kettering Cancer Center, New York, NY, 10021, USA
SOURCE: Clinical Cancer Research (2001), 7(4), 962-970
CODEN: CCREF4; ISSN: 1078-0432
PUBLISHER: American Association for Cancer Research
DOCUMENT TYPE: Journal
LANGUAGE: English
AB We have synthesized a series of hybrid polar compds. that induce differentiation and/or apoptosis of various transformed cells. These agents are also potent inhibitors of histone deacetylases (HDACs). Pyroxamide (suberoyl-3-aminopyridineamide hydroxamic acid) is a new member of this class of compds. that is currently under development as an anticancer agent. We investigated the activity of pyroxamide as an inducer of differentiation and/or apoptosis in transformed cells. Pyroxamide, at micromolar concns., induced terminal differentiation in murine erythroleukemia (MEL) cells and caused growth inhibition by cell cycle arrest and/or apoptosis in MEL, prostate carcinoma, bladder carcinoma, and neuroblastoma cells. Administration of pyroxamide (100 or 200 mg/kg/day) to nude mice at doses that caused little evident toxicity significantly suppressed the growth of s.c. CWR22 prostate cancer xenografts. Despite the potent growth-inhibitory effects of pyroxamide in this tumor model, serum prostate-specific antigen levels in control vs. pyroxamide-treated mice were not significantly different. Pyroxamide is a potent inhibitor of affinity-purified HDAC1 (ID50 = 100 nM) and causes the accumulation of acetylated core histones in MEL cells cultured with the agent. Human CWR22 prostate tumor xenografts from mice treated with pyroxamide (100 or 200 mg/kg/day) showed increased levels of histone acetylation and increased expression of the cell cycle regulator p21/WAF1, compared with tumors from vehicle-treated control animals. The findings suggest that pyroxamide may be a useful agent for the treatment of malignancy and that induction of p21/WAF1 in transformed cells by pyroxamide may contribute to the antitumor effects of this agent.
IT 382180-17-8, Pyroxamide
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological

activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antitumor effects of pyroxamide, an inhibitor of histone deacetylase)
RN 382180-17-8 CAPLUS
CN Octanediamide, N1-hydroxy-N8-3-pyridinyl- (CA INDEX NAME)



IT 9076-57-7, Histone deacetylase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(antitumor effects of pyroxamide, an inhibitor of histone deacetylase)
RN 9076-57-7 CAPLUS
CN Deacetylase, histone (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
REFERENCE COUNT: 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L42 ANSWER 52 OF 56 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2001:185885 CAPLUS <<LOGINID::20080505>>
DOCUMENT NUMBER: 134:237397
TITLE: Preparation of alkanoic acid derivatives as novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof
INVENTOR(S): Richon, Victoria M.; Marks, Paul A.; Rifkind, Richard A.; Breslow, Ronald; Belvedere, Sandro; Gershell, Leland; Miller, Thomas A.
PATENT ASSIGNEE(S): Sloan-Kettering Institute for Cancer Research, USA; Trustees of Columbia University in the City of New York
SOURCE: PCT Int. Appl., 142 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001018171	A2	20010315	WO 2000-US23232	20000824 <--
WO 2001018171	A3	20020627		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,

DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,
CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2383999	A1	20010315	CA 2000-2383999		20000824 <--
AU 2000069327	A	20010410	AU 2000-69327		20000824 <--
EP 1231919	A2	20020821	EP 2000-957757		20000824 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL					
BR 2000014254	A	20020827	BR 2000-14254		20000824 <--
HU 2002002707	A2	20021228	HU 2002-2707		20000824 <--
HU 2002002707	A3	20031128			
US 6511990	B1	20030128	US 2000-645430		20000824 <--
JP 2003509343	T	20030311	JP 2001-522383		20000824 <--
NZ 517613	A	20040130	NZ 2000-517613		20000824 <--
ZA 2002001544	A	20021010	ZA 2002-1544		20020225 <--
MX 2002PA02505	A	20040910	MX 2002-PA2505		20020307 <--
US 20040002506	A1	20040101	US 2002-281875		20021025 <--
US 7126001	B2	20061024			
AU 2005205805	A1	20050929	AU 2005-205805		20050902 <--
US 20060241129	A1	20061026	US 2006-474043		20060622 <--
US 7345174	B2	20080318			
US 20070010536	A1	20070111	US 2006-473839		20060622 <--
US 20070010669	A1	20070111	US 2006-474042		20060622 <--
PRIORITY APPLN. INFO.:			US 1999-152755P	P	19990908 <--
			US 2000-208688P	P	20000601 <--
			AU 2000-69327	A3	20000824 <--
			US 2000-645430	A1	20000824 <--
			WO 2000-US23232	W	20000824 <--
			US 2002-281875	A3	20021025 <--

OTHER SOURCE(S): MARPAT 134:237397

AB The present invention provides the compound having formula R1NHCOCH(AR2)(CH2)nCONHOH (wherein each of R1 and R2 is, substituted or unsubstituted, aryl, cycloalkyl, cycloalkylamino, naphtha, pyridineamino, piperidino, tert-Bu, aryloxy, arylalkyloxy, or pyridine group; wherein A is an amido moiety, O, S, NH, or CH2; and wherein n is an integer from 3 to 8). The present invention also provides a method of selectively inducing growth arrest, terminal differentiation and/or apoptosis of neoplastic cells and thereby inhibiting proliferation of such cells. Moreover, the present invention provides a method of treating a patient having a tumor characterized by proliferation of neoplastic cells. Lastly, the present invention provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically acceptable amount of the compound above. Thus, N-benzoyl-L-α-aminosuberateanilide, i.e. PhCO-Asu-NHPh, was condensed with tert-butyldiphenylsilyloxyamine using 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride in CH2Cl2 at room temperature for 12 h, followed by deprotection with 5% CF3CO2H in CH2Cl2 for 1.5 h to give PhCO-Asu(NHOH)-NHPh (I). I and PhCH2O2C-Asu(NHOH)-NHR (R = quinolin-8-yl) showed activity of murine erythroleukemia cell (MEL) differentiation at 200 and 40 nM, resp., and inhibited histone deacetylase (HDAC) with ID50 of 1 and <10 nM, resp.

IT 149647-78-9P 329966-65-6P 329966-66-7P
329966-67-8P 329966-68-9P 329966-69-0P
329966-77-0P 329966-91-8P 329966-92-9P
329966-97-4P 329966-98-5P 329967-00-2P
329967-01-3P 329967-02-4P 329967-03-5P
329967-19-3P 329967-32-0P 329967-33-1P

329967-35-3P 329967-37-5P 329967-38-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of alkanoic acid derivs. as novel class of cytodifferentiating agents and histone deacetylase inhibitors)

RN 149647-78-9 CAPLUS
CN Octanediamide, N1-hydroxy-N8-phenyl- (CA INDEX NAME)



RN 329966-65-6 CAPLUS
CN Octanediamide, N8-hydroxy-N1-phenyl-2-[(3-quinolinylcarbonyl)amino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 329966-66-7 CAPLUS
CN Octanediamide, N8-hydroxy-N1-phenyl-2-[(2-thienylcarbonyl)amino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 329966-67-8 CAPLUS
CN 1,1,6-Hexanetricarboxamide, N6-hydroxy-N1,N1'-diphenyl- (9CI) (CA INDEX NAME)



RN 329966-68-9 CAPLUS
CN 1,1,6-Hexanetricarboxamide, N6-hydroxy-N1,N1'-di-8-quinolinyl- (9CI) (CA INDEX NAME)



RN 329966-69-0 CAPLUS
CN Octanediamide, N-hydroxy-N'-8-quinolinyl- (9CI) (CA INDEX NAME)



RN 329966-77-0 CAPLUS
CN Octanediamide, N8-hydroxy-N1-3-quinolinyl-2-[(3-quinolinylcarbonyl)amino]- (CA INDEX NAME)



RN 329966-91-8 CAPLUS
CN 1,1,6-Hexanetricarboxamide, N6-hydroxy-N1,N1'-di-5-quinolinyl- (9CI) (CA INDEX NAME)



RN 329966-92-9 CAPLUS
CN 1,1,6-Hexanetricarboxamide, N6-hydroxy-N1,N1'-di-6-quinolinyl- (9CI) (CA INDEX NAME)



RN 329966-97-4 CAPLUS
CN Octanediamide, 2-(benzoylamino)-N8-hydroxy-N1-phenyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 329966-98-5 CAPLUS
CN Octanediamide, N8-hydroxy-N1-phenyl-2-[(3-pyridinylcarbonyl)amino]-, (2S)-
(CA INDEX NAME)

Absolute stereochemistry.



RN 329967-00-2 CAPLUS
CN Carbamic acid, N-[(1S)-7-(hydroxyamino)-7-oxo-1-
[(phenylamino)carbonyl]heptyl]-, phenylmethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 329967-01-3 CAPLUS
CN Carbamic acid, N-[(1S)-7-(hydroxyamino)-7-oxo-1-[(8-
quinolinylamino)carbonyl]heptyl]-, phenylmethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 329967-02-4 CAPLUS
CN Octanediamide, 2-(benzoylamino)-N8-hydroxy-N1-8-quinolinyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 329967-03-5 CAPLUS
CN Carbamic acid, [(1R)-7-(hydroxyamino)-7-oxo-1-[(8-quinolinylamino)carbonyl]heptyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 329967-19-3 CAPLUS
CN Octanediamide, 2-[(cyclohexylcarbonyl)amino]-N8-hydroxy-N1-phenyl-, (2S)-

(CA INDEX NAME)

Absolute stereochemistry.



RN 329967-32-0 CAPLUS
CN Octanediamide, 2-(benzoylamino)-N8-hydroxy-N1-phenyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 329967-33-1 CAPLUS
CN Carbamic acid, [7-(hydroxyamino)-7-oxo-1-[(phenylamino)carbonyl]heptyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 329967-35-3 CAPLUS
CN Carbamic acid, [7-(hydroxyamino)-7-oxo-1-[(8-quinolinylamino)carbonyl]heptyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 329967-37-5 CAPLUS
CN Octanediamide, N8-hydroxy-N1-phenyl-2-[(3-pyridinylcarbonyl)amino]-, (2R)-
(CA INDEX NAME)

Absolute stereochemistry.



RN 329967-38-6 CAPLUS
CN Octanediamide, 2-(benzoylamino)-N8-hydroxy-N1-8-quinolinyl-, (2R)- (CA
INDEX NAME)

Absolute stereochemistry.



IT 9076-57-7, Histone deacetylase
RL: BPR (Biological process); BSU (Biological study, unclassified); MSC
(Miscellaneous); BIOL (Biological study); PROC (Process)
(preparation of alkanoic acid derivs. as novel class of cytodifferentiating
agents and histone deacetylase inhibitors)
RN 9076-57-7 CAPLUS
CN Deacetylase, histone (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L42 ANSWER 53 OF 56 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2001:185791 CAPLUS <<LOGINID::20080505>>
DOCUMENT NUMBER: 134:204354
TITLE: Crystal structure of a histone deacetylase-like protein from Aquifex aeolicus and complexes with inhibitors
INVENTOR(S): Pavletich, Nikola; Finnin, Michael; Donigian, Jill; Richon, Victoria; Rifkind, Richard A.; Marks, Paul A.; Breslow, Ronald
PATENT ASSIGNEE(S): Sloan-Kettering Institute for Cancer Research, USA; Trustees of Columbia University in the City of New York
SOURCE: PCT Int. Appl., 329 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE	
WO 2001018045	A1	20010315	WO 2000-US24700		20000908	<--
WO 2001018045	A9	20021107				
W: CA, JP, US						
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE						
CA 2383885	A1	20010315	CA 2000-2383885		20000908	<--
EP 1212357	A1	20020612	EP 2000-968344		20000908	<--
EP 1212357	B1	20070502				
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY						
JP 2003518923	T	20030617	JP 2001-522267		20000908	<--
AT 361316	T	20070515	AT 2000-968344		20000908	<--
ES 2287033	T3	20071216	ES 2000-968344		20000908	<--
US 20030013176	A1	20030116	US 2002-95109		20020308	<--
US 7124068	B2	20061017				
US 20070087427	A1	20070419	US 2006-505214		20060816	<--
US 20070100559	A1	20070503	US 2006-505196		20060816	<--
PRIORITY APPLN. INFO.:			US 1999-152753P	P	19990908	<--
			WO 2000-US24700	W	20000908	<--
			US 2002-95109	A3	20020308	<--

AB The present invention provides three-dimensional structural information of the histone deacetylase-like protein (HDLP) from the hyperthermophilic bacterium Aquifex aeolicus. HDLP shares 35.2% amino acid sequence identity with human histone deacetylase (HDAC1). The double mutant C75S/C77S of HDLP is used to facilitate the determination of three-dimensional structure of HDLP bound to a zinc atom at its zinc atom-binding site. The present invention further provides three-dimensional structural information of HDLP double mutant bound by inhibitor mols. (e.g., trichostatin A or suberoyl anilide hydroxamic acid). The three-dimensional structural information of the present invention is useful to design, isolate and screen deacetylase inhibitor compds. capable of inhibiting HDLP, HDAC family members, and HDLP-related mols. The

invention also relates to nucleic acids encoding a mutant HDLP which facilitates the determination of the three-dimensional structure of HDLP in the presence of a zinc atom.

IT 9076-57-7, Histone deacetylase
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(HDAC (histone deacetylase-like protein); crystal structure of a histone deacetylase-like protein from Aquifex aeolicus and complexes with inhibitors)
RN 9076-57-7 CAPLUS
CN Deacetylase, histone (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
IT 204795-19-7, Histone deacetylase-like protein (Aquifex aeolicus gene acuC1) 328980-16-1
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(amino acid sequence; crystal structure of a histone deacetylase-like protein from Aquifex aeolicus and complexes with inhibitors)
RN 204795-19-7 CAPLUS
CN Protein (Aquifex aeolicus gene acuC1 histone deacetylase-like) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 328980-16-1 CAPLUS
CN Histone deacetylase-like protein [75-serine,77-serine] (Aquifex aeolicus gene acuC1) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
IT 149647-78-9D, complex with deacetylase protein
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(crystal structure of a histone deacetylase-like protein from Aquifex aeolicus and complexes with inhibitors)
RN 149647-78-9 CAPLUS
CN Octanediamide, N1-hydroxy-N8-phenyl- (CA INDEX NAME)

IT 328980-17-2
RL: BUU (Biological use, unclassified); PRP (Properties); BIOL (Biological study); USES (Uses)
(nucleotide sequence; crystal structure of a histone deacetylase-like protein from Aquifex aeolicus and complexes with inhibitors)
RN 328980-17-2 CAPLUS
CN DNA (Aquifex aeolicus gene acuC1 histone deacetylase-like protein [75-serine,77-serine]-specifying) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L42 ANSWER 54 OF 56 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2000:702583 CAPLUS <<LOGINID::20080505>>
DOCUMENT NUMBER: 134:272
TITLE: Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo
AUTHOR(S): Butler, Lisa M.; Agus, David B.; Scher, Howard I.; Higgins, Brian; Rose, Adam; Cordon-Cardo, Carlos; Thaler, Howard T.; Rifkind, Richard A.; Marks, Paul A.; Richon, Victoria M.
CORPORATE SOURCE: Cell Biology Program, Memorial Sloan-Kettering Cancer Center, New York, NY, 10021, USA
SOURCE: Cancer Research (2000), 60(18), 5165-5170
CODEN: CNREA8; ISSN: 0008-5472
PUBLISHER: American Association for Cancer Research
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Suberoylanilide hydroxamic acid (SAHA) is the prototype of a family of hybrid polar compds. that induce growth arrest in transformed cells and show promise for the treatment of cancer. SAHA induces differentiation and/or apoptosis in certain transformed cells in culture and is a potent inhibitor of histone deacetylases. In this study, we examined the effects of SAHA on the growth of human prostate cancer cells in culture and on the growth of the CWR22 human prostate xenograft in nude mice. SAHA suppressed the growth of the LNCaP, PC-3, and TSU-Pr1 cell lines at micromolar concns. (2.5-7.5 μM). SAHA induced dose-dependent cell death in the LNCaP cells. In mice with transplanted CWR22 human prostate tumors, SAHA (25, 50, and 100 mg/kg/day) caused significant suppression of tumor growth compared with mice receiving vehicle alone; treatment with 50 mg/kg/day resulted in a 97% reduction in the mean final tumor volume compared with controls. At this dose, there was no detectable toxicity as evaluated by weight gain and necropsy examination Increased accumulation of acetylated core histones was detected in the CWR22 tumors within 6 h of SAHA administration. SAHA induced prostate-specific antigen mRNA expression in CWR22 prostate cancer cells, resulting in higher levels of serum prostate-specific antigen than predicted from tumor volume alone. The results suggest that hydroxamic acid-based hybrid polar compds. inhibit prostate cancer cell growth and may be useful, relatively nontoxic agents for the treatment of prostate carcinoma.

IT 149647-78-9
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(suberoylanilide hydroxamic acid suppresses the growth of prostate cancer cells in vitro and in vivo)
RN 149647-78-9 CAPLUS
CN Octanediamide, N1-hydroxy-N8-phenyl- (CA INDEX NAME)



IT 9076-57-7, Histone deacetylase
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(suberoylanilide hydroxamic acid suppresses the growth of prostate cancer cells in vitro and in vivo)
RN 9076-57-7 CAPLUS
CN Deacetylase, histone (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L42 ANSWER 55 OF 56 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2000:633220 CAPLUS <<LOGINID::20080505>>
DOCUMENT NUMBER: 133:360372
TITLE: Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation
AUTHOR(S): Richon, Victoria M.; Sandhoff, Todd W.; Rifkind, Richard A.; Marks, Paul A.
CORPORATE SOURCE: DeWitt Wallace Research Laboratory, Cell Biology Program, Memorial Sloan-Kettering Cancer Center and Graduate School of Medical Sciences of Cornell Medical School, New York, NY, 10021, USA
SOURCE: Proceedings of the National Academy of Sciences of the United States of America (2000), 97(18), 10014-10019
CODEN: PNASA6; ISSN: 0027-8424
PUBLISHER: National Academy of Sciences
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Histone deacetylases (HDACs) catalyze the removal of acetyl groups on the amino-terminal lysine residues of core nucleosomal histones. This activity is associated generally with transcriptional repression. We have reported previously that inhibition of HDAC activity by hydroxamic acid-based hybrid polar compds., such as suberoylanilide hydroxamic acid (SAHA), induces differentiation and/or apoptosis of transformed cells in vitro and inhibits tumor growth in vivo. SAHA is a potentially new therapeutic approach to cancer treatment and is in Phase I clin. trials. In several tumor cell lines examined, HDAC inhibitors alter the expression of less than 1% of expressed genes, including the cell cycle kinase inhibitor p21WAF1. In T24 bladder carcinoma cells, SAHA induces up to a 9-fold increase in p21WAF1 mRNA and protein, which is, at least in part, because of an increase in the rate of transcription of the gene. SAHA causes an accumulation of acetylated histones H3 and H4 in total cellular chromatin by 2 h, which is maintained through 24 h of culture. An increase in the accumulation of acetylated H3 and H4 was detected throughout the p21WAF1 promoter and the structural gene after culture with SAHA. The level of histone acetylation did not change in chromatin associated with the actin and p27 genes, and their mRNA expression was not altered during culture of T24 cells with SAHA. Thus, the present findings indicate that the induction of p21WAF1 by SAHA is regulated, at least in part, by the degree of acetylation of the gene-associated histones and that this induced increase in acetylation is gene selective.
IT 9076-57-7, Histone deacetylase
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL

(Biological study); PROC (Process)
(inhibition; histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation)
RN 9076-57-7 CAPLUS
CN Deacetylase, histone (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
IT 149647-78-9
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(inhibitor; histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation)
RN 149647-78-9 CAPLUS
CN Octanediamide, N1-hydroxy-N8-phenyl- (CA INDEX NAME)

REFERENCE COUNT: 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L42 ANSWER 56 OF 56 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2000:277883 CAPLUS <<LOGINID::20080505>>
DOCUMENT NUMBER: 132:318052
TITLE: Modulation of gene expression by combination therapy with antisense oligonucleotide and gene product protein effector
INVENTOR(S): Besterman, Jeffrey M.; Macleod, Alan Robert; Siders, William M.
PATENT ASSIGNEE(S): Methylgene, Inc., Can.
SOURCE: PCT Int. Appl., 99 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000023112	A1	20000427	WO 1999-US24278	19991019 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2347003	A1	20000427	CA 1999-2347003	19991019 <--
AU 9965194	A	20000508	AU 1999-65194	19991019 <--
AU 766084	B2	20031009		

```
     EP 1123111           A1    20010816    EP 1999-953211          19991019 <--
     EP 1123111           B1    20040915
          R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
              IE, SI, LT, LV, FI, RO
     JP 2002528391        T     20020903    JP 2000-576885          19991019 <--
     EP 1243289           A2    20020925    EP 2002-14370           19991019 <--
     EP 1243289           A3    20040317
          R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
              IE, FI, CY
     EP 1243290           A2    20020925    EP 2002-14371           19991019 <--
     EP 1243290           A3    20040317
          R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
              IE, FI, CY
     AT 275956            T     20041015    AT 1999-953211          19991019 <--
     ES 2228119           T3    20050401    ES 1999-953211          19991019 <--
     US 6953783           B1    20051011    US 1999-420692          19991019 <--
     US 20030096777       A1    20030522    US 2002-145493          20020514 <--
     AU 2004200032        A1    20040129    AU 2004-200032          20040106 <--
     AU 2004200032        B2    20050505
PRIORITY APPLN. INFO.:                      US 1998-104804P     P   19981019 <--
                                            AU 1999-65194       A3  19991019 <--
                                            EP 1999-953211      A3  19991019 <--
                                            US 1999-420692      A3  19991019 <--
                                            WO 1999-US24278     W   19991019 <--
```

AB The invention relates to the modulation of gene expression. In particular, the invention relates to compns. comprising antisense oligonucleotides which inhibit expression of a gene in operable association with protein effectors of a product of that gene, and methods of using the same. In addition, the invention relates to the modulation of mammalian gene expression regulated by methylation.

IT 149647-78-9
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antisense oligonucleotide and gene product protein effector for gene expression modulation)

RN 149647-78-9 CAPLUS

CN Octanediamide, N1-hydroxy-N8-phenyl- (CA INDEX NAME)

IT 9076-57-7, Histone deacetylase
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(antisense oligonucleotide and gene product protein effector for gene expression modulation)

RN 9076-57-7 CAPLUS

CN Deacetylase, histone (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>